<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">14756</article-id><article-id pub-id-type="doi">10.7554/eLife.14756</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-34848"><name><surname>Qi</surname><given-names>Shuhong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-51781"><name><surname>Li</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-51784"><name><surname>Lu</surname><given-names>Lisen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-51782"><name><surname>Qi</surname><given-names>Zhongyang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-51783"><name><surname>Liu</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66776"><name><surname>Chen</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66777"><name><surname>Shen</surname><given-names>Guanxin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-51785"><name><surname>Fu</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-51788"><name><surname>Luo</surname><given-names>Qingming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-41684"><name><surname>Zhang</surname><given-names>Zhihong</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5227-8926</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Britton Chance Center for Biomedical Photonics</institution>, <institution>Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology</institution>, <addr-line><named-content content-type="city">Wuhan</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering</institution>, <institution>Huazhong University of Science and Technology</institution>, <addr-line><named-content content-type="city">Wuhan</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Immunology, Tongji Medical College</institution>, <institution>Huazhong University of Science and Technology</institution>, <addr-line><named-content content-type="city">Wuhan</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cao</surname><given-names>Xuetao</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>Zhejiang University School of Medicine</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>qluo@mail.hust.edu.cn</email> (QL);</corresp><corresp id="cor2"><email>czyzzh@mail.hust.edu.cn</email> (ZZ)</corresp><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e14756</elocation-id><history><date date-type="received"><day>28</day><month>01</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Qi et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Qi et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-14756-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.14756.001</object-id><p>The combined-immunotherapy of adoptive cell therapy (ACT) and cyclophosphamide (CTX) is one of the most efficient treatments for melanoma patients. However, no synergistic effects of CTX and ACT on the spatio-temporal dynamics of immunocytes in vivo have been described. Here, we visualized key cell events in immunotherapy-elicited immunoreactions in a multicolor-coded tumor microenvironment, and then established an optimal strategy of metronomic combined-immunotherapy to enhance anti-tumor efficacy. Intravital imaging data indicated that regulatory T cells formed an 'immunosuppressive ring' around a solid tumor. The CTX-ACT combined-treatment elicited synergistic immunoreactions in tumor areas, which included relieving the immune suppression, triggering the transient activation of endogenous tumor-infiltrating immunocytes, increasing the accumulation of adoptive cytotoxic T lymphocytes, and accelerating the infiltration of dendritic cells. These insights into the spatio-temporal dynamics of immunocytes are beneficial for optimizing immunotherapy and provide new approaches for elucidating the mechanisms underlying the involvement of immunocytes in cancer immunotherapy.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.001">http://dx.doi.org/10.7554/eLife.14756.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.14756.002</object-id><title>eLife digest</title><p>Melanoma is a form of skin cancer that is particularly difficult to treat. A new approach that has shown a lot of promise in treating many different cancers, including melanoma, is called “immunotherapy”. This technique harnesses the immune system – the body’s natural defences that help to protect against infections and disease – to combat cancer.</p><p>One powerful type of immunotherapy involves injecting patients with cells called lymphocytes, which form part of the immune system. This is known as adoptive cell therapy and can activate the immune system to fight cancer, helping to shrink tumors. This treatment can be made even more powerful by combining it with a drug called cyclophosphamide and this combination, known as CTX-ACT, is currently one of the most efficient treatments for melanoma. Yet, little information is available to indicate why this treatment is so effective.</p><p>Using mice implanted with melanoma cells, Qi, Li et al. sought to understand how CTX-ACT treatment works, with the goal of optimising it to increase its success. The results showed that a protective barrier of immune cells that suppresses the anti-tumor immune response – called an “immunosuppressive ring” – surrounds untreated tumors. CTX-ACT treatment can breakdown these rings, helping to reactivate the anti-tumor immune reaction in the tumors. This allows both the injected and mouse’s own immune cells to move into the tumor and destroy cancer cells.</p><p>Qi, Li et al. used their findings to optimise treatment and succeeded in controlling tumor growth in the mice for several weeks. These new insights could be used to improve current immunotherapies, and offer new approaches for investigating the involvement of immune cells in the treatment of a wide range of different cancers.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.002">http://dx.doi.org/10.7554/eLife.14756.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>intravital imaging</kwd><kwd>regulatory T cells</kwd><kwd>multicolor-coded</kwd><kwd>immunocytes</kwd><kwd>tumor microenvironment</kwd><kwd>immunotherapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>91442201</award-id><principal-award-recipient><name><surname>Qi</surname><given-names>Shuhong</given-names></name><name><surname>Lu</surname><given-names>Lisen</given-names></name><name><surname>Liu</surname><given-names>Lei</given-names></name><name><surname>Zhang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002855</institution-id><institution>Ministry of Science and Technology of the People's Republic of China</institution></institution-wrap></funding-source><award-id>2011CB910401</award-id><principal-award-recipient><name><surname>Qi</surname><given-names>Shuhong</given-names></name><name><surname>Li</surname><given-names>Hui</given-names></name><name><surname>Liu</surname><given-names>Lei</given-names></name><name><surname>Luo</surname><given-names>Qingming</given-names></name><name><surname>Zhang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>61421064</award-id><principal-award-recipient><name><surname>Fu</surname><given-names>Ling</given-names></name><name><surname>Luo</surname><given-names>Qingming</given-names></name><name><surname>Zhang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002338</institution-id><institution>Ministry of Education of the People's Republic of China</institution></institution-wrap></funding-source><award-id>2015ZDTD014</award-id><principal-award-recipient><name><surname>Qi</surname><given-names>Shuhong</given-names></name><name><surname>Lu</surname><given-names>Lisen</given-names></name><name><surname>Liu</surname><given-names>Lei</given-names></name><name><surname>Zhang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002855</institution-id><institution>Ministry of Science and Technology of the People's Republic of China</institution></institution-wrap></funding-source><award-id>Director fund of Wuhan National Laboratory for Optoelectronics</award-id><principal-award-recipient><name><surname>Qi</surname><given-names>Shuhong</given-names></name><name><surname>Lu</surname><given-names>Lisen</given-names></name><name><surname>Liu</surname><given-names>Lei</given-names></name><name><surname>Luo</surname><given-names>Qingming</given-names></name><name><surname>Zhang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Tregs form an &quot;immunosuppressive ring&quot; around solid tumors that is broken down during adoptive cell therapy and cyclophosphamide combination immunotherapy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cancer immunotherapy has been an area of significant process in recent decades, and is considered a breakthrough in cancer therapy (<xref ref-type="bibr" rid="bib18">Couzin-Frankel, 2013</xref>). Current promising techniques in cancer immunotherapy are the use of monoclonal antibodies (mAbs), tumor vaccines, and adoptive cell therapy (ACT) (<xref ref-type="bibr" rid="bib21">Elert, 2013</xref>; <xref ref-type="bibr" rid="bib17">Couzin-Frankel and McNutt, 2013</xref>). ACT has been reported to be one of the most efficient treatments for patients with melanoma because it effectively elicits anti-tumor immune responses and leads to objective tumor regression in more than 50% of patients (<xref ref-type="bibr" rid="bib44">Pittet et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Rosenberg et al., 2008</xref>). During the immunotherapy-elicited immune response, various immune cells, including endogenous and adoptive immunocytes, are activated in the tumor microenvironment (<xref ref-type="bibr" rid="bib53">Schreiber et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Gajewski et al., 2013</xref>). However, the underlying process remains a ‘black box’ because, whereas information is available to describe the input (immunotherapy) and the output (tumor elimination), relatively limited information is available to describe the spatio-temporal changes in the participating immune cells in the tumor microenvironment (<xref ref-type="bibr" rid="bib28">Krummel, 2010</xref>). Traditional biological methods, such as immunohistochemistry methods or flow cytometry, have revealed the type and function of immune cells that play a role at certain time-points during the anti-tumor reaction (<xref ref-type="bibr" rid="bib42">Perentes et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Boissonnas et al., 2013</xref>). Visualization of the dynamic characteristics of immunocytes, including their movement, migration, and recruitment, as well as of the interaction between immunocytes and tumor cells in the systemic environment, is critical for understanding the success or failure of cancer immunotherapy on a mechanistic level (<xref ref-type="bibr" rid="bib28">Krummel, 2010</xref>; <xref ref-type="bibr" rid="bib10">Bourzac, 2013</xref>).</p><p>The common strategy used in clinical trials of ACT is to isolate tumor antigen-specific lymphocytes from patients, robustly expand these cells in vitro, and infuse them into cancer patients (<xref ref-type="bibr" rid="bib63">Yee et al., 2002</xref>; <xref ref-type="bibr" rid="bib31">Mackensen et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Benlalam et al., 2007</xref>). The activity and cytotoxicity of tumor-specific cytotoxic T lymphocytes (CTLs) have long been considered the crucial factors for the efficacy of ACT against solid tumors (<xref ref-type="bibr" rid="bib9">Boon, 1994</xref>). However, recent reports have indicated that despite the detection of tumor-reactive CTLs in the bloodstream after the adoptive transfer, most CTLs lost their anti-tumor functions as a result of endogenous immunosuppressive networks in the tumor microenvironment (<xref ref-type="bibr" rid="bib65">Zippelius et al., 2004</xref>; <xref ref-type="bibr" rid="bib3">Baitsch et al., 2011</xref>). Foxp3<sup>+</sup> regulatory T cells (Tregs) play a key immunosuppressive role in the endogenous immunosuppressive networks (<xref ref-type="bibr" rid="bib19">Curiel et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">Vignali et al., 2008</xref>). Various immunosuppressive mechanisms associated with Tregs have been revealed, including their specific recruitment and accumulation in the tumor stroma (<xref ref-type="bibr" rid="bib60">Wang et al., 2004</xref>; <xref ref-type="bibr" rid="bib38">Nishikawa and Sakaguchi, 2014</xref>), suppression of the CTL function by TGF-β (<xref ref-type="bibr" rid="bib16">Chen et al., 2005</xref>), and induction of the CTL dysfunction by interactions of Tregs with intratumoral dendritic cells (DCs) (<xref ref-type="bibr" rid="bib4">Bauer et al., 2014</xref>). However, the details of the spatio-temporal orchestration of Tregs associated with tumor progression, the contributions of the Treg distribution in tumor stroma to immunosuppressive networks, and the effect of Tregs on the infiltration of adoptive CTLs into solid tumors remain unclear.</p><p>Treg elimination is considered to be an essential component for disrupting the immunosuppressive networks in the tumor microenvironment before ACT (<xref ref-type="bibr" rid="bib49">Rosenberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Antony et al., 2005</xref>). Cyclophosphamide (CTX) is a commonly used alkylating agent in chemotherapy, which has been applied in recent years to selectively suppress, abrogate and deplete Tregs before ACT treatment (<xref ref-type="bibr" rid="bib49">Rosenberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Nishikawa and Sakaguchi, 2014</xref>; <xref ref-type="bibr" rid="bib39">Oleinika et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Zhao et al., 2010</xref>). Lymphodepletion before ACT by CTX treatment further promoted tumor-specific CTL infiltration into the target tumors (<xref ref-type="bibr" rid="bib11">Bracci et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Rosenberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib8">Boissonnas et al., 2013</xref>). The migratory behavior of effector T cells in solid tumors has been analyzed by two-photon microscopy, proving that migration presents the critical step for the sufficient infiltration of T cells into the solid tumor and promotes tumor elimination (<xref ref-type="bibr" rid="bib35">Mrass et al., 2006</xref>; <xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>). However, the influence of CTX treatment on the long-term precise migratory behavior of adoptive CTLs in solid tumors has not been directly observed in vivo.</p><p>In addition to the selective depletion and suppression of Tregs, other immunomodulatory mechanisms of CTX treatment include the systemic activation of DCs (<xref ref-type="bibr" rid="bib46">Radojcic et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Veltman et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Nakahara et al., 2010</xref>), increase of the infiltration of DCs into the tumor area (<xref ref-type="bibr" rid="bib51">Schiavoni et al., 2011</xref>), and promotion of the penetration of CTLs into the tumor parenchyma (<xref ref-type="bibr" rid="bib8">Boissonnas et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Bracci et al., 2007</xref>). Although certain immunomodulatory functions of CTX alone or in combination with immunotherapy have been proposed previously, the synergistically enhanced effects of the combined CTX and ACT (CTX-ACT) treatment on the adoptive and endogenous anti-tumor immunoreactions have not been revealed. In particular, the dynamic effects of the CTX-ACT treatment on endogenous immune cells (such as CTLs, neutrophils and DCs) in the tumor microenvironment have not been well described. Using intravital microscopy and a skin-fold window chamber model, we captured a long-term comprehensive sequence of cellular events associated with multicolor-coded tumor cells, adoptive CTLs, endogenous CTLs, Tregs, DCs and tumor-infiltrating immunocytes in the tumor microenvironment during CTX-ACT combined-immunotherapy for B16 melanoma. The long-term intravital imaging data provided direct evidence for the synergetic anti-tumor immune-enhanced effects of the CTX-ACT combination treatment, including the elimination of Tregs, activation of the endogenous tumor-infiltrating immunocytes, and infiltration of adoptive and endogenous CTLs and DCs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Limited effect of adoptive CTLs on B16 tumor cells in vivo</title><p>To assess the curative efficacy of ACT on murine melanoma in vivo, CTLs were obtained from the splenocytes of C57BL/6 mice immunized with mitomycin C pre-treated B16 melanoma cells according to previous protocols (<xref ref-type="bibr" rid="bib48">Restifo and Nicholas, 2011</xref>) and reports (<xref ref-type="bibr" rid="bib29">Liu et al., 2006</xref>; <xref ref-type="bibr" rid="bib4">Bauer et al., 2014</xref>). Here, the activity and cytotoxicity of CTLs against target tumor cells were demonstrated in vitro by flow cytometry of B16 tumor cells that stably express mutants of the cyan fluorescent protein mCerulean (CFP-B16 tumor cells, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), which is minimally immunogenic in C57BL/6 mice (<xref ref-type="bibr" rid="bib55">Skelton et al., 2001</xref>; <xref ref-type="bibr" rid="bib61">Yang et al., 2016</xref>). However, the ACT treatment failed to control the tumor growth (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), which is consistent with the results reported for certain clinical cases (<xref ref-type="bibr" rid="bib65">Zippelius et al., 2004</xref>; <xref ref-type="bibr" rid="bib36">Mukai et al., 1999</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.003</object-id><label>Figure 1.</label><caption><title>‘Immunosuppressive ring’ formed by Tregs in CFP-B16 tumor-bearing mice, which inhibited the anti-tumor efficacy of the adoptive CTLs.</title><p>(<bold>A</bold>) Tumor growth curves for CFP-B16 tumors of mice treated with ACT or PBS control. The data are represented as the mean ± SEM tumor volume (n = 12–14, three independent experiments). ns: not significant, (<xref ref-type="supplementary-material" rid="SD1-data">Figure 1—source data 1</xref>). (<bold>B</bold>) Density of <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Carboxyfluorescein_succinimidyl_ester">carboxyfluorescein succinimidyl ester</ext-link> (CFSE)-labeled CTLs within different organs (tumor-draining lymph nodes (TDLNs), non-tumor-draining lymph nodes (NDLNs), spleens, and tumors). The density was determined by counting the number of CFSE-labeled CTLs per mm<sup>2</sup> on frozen tissue sections. The data are represented as the mean ± SEM (n = 18–22 fields, 0.18 mm<sup>2</sup> per field) from three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, (<xref ref-type="supplementary-material" rid="SD2-data">Figure 1—source data 2</xref>). (<bold>C</bold>) Large-field intravital images of an ‘immunosuppressive ring’ around the CFP-B16 tumor. Blue – CFP-B16 tumor; red – Tregs (<italic>Foxp3</italic>-mRFP cells); green – CFSE-labeled CTLs. The left panel shows different single color channels of the tumor microenvironment, and the right panel shows the three color channels merged. Scale bar: 500 µm. (<bold>D</bold>) Schematic diagram of the ‘immunosuppressive ring’ in the tumor microenvironment.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.003">http://dx.doi.org/10.7554/eLife.14756.003</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.14756.004</object-id><label>Figure 1—source data 1.</label><caption><title>Tumor growth curves for CFP-B16 tumors of mice treated with ACT or PBS.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.004">http://dx.doi.org/10.7554/eLife.14756.004</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig1-data1-v2.pzf"/></supplementary-material></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.14756.005</object-id><label>Figure 1—source data 2.</label><caption><title>Density of CFSE-labeled CTLs within different organs.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.005">http://dx.doi.org/10.7554/eLife.14756.005</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig1-data2-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.006</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Establishment and characterization of CFP-B16 tumor-specific CTLs.</title><p>(<bold>A</bold>) CFSE- and propidium iodine (PI)-based assays to assess the cytotoxicity of CTLs added to the CFP-B16 tumor cells or added to the splenocytes by flow cytometry, and the control group which was composed of splenocytes added to the CFP-B16 tumor cells. The data are represented as the mean ± SD from three independent experiments. (<bold>B</bold>) Analysis and characterization of the in vitro-activated CTLs. The data are representative of similar results from three independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.006">http://dx.doi.org/10.7554/eLife.14756.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.007</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Fluorescence microscopy images showing the distribution of CFSE-labeled CTLs in different organs.</title><p>Representative sections of tumor-draining lymph node (TDLN), non-tumor-draining lymph node (NDLN), spleen and tumor tissues were collected from tumor-bearing mice on Days 1–3 (early stage) and Days 4–6 (late stage) after the adoptive transfer of CTLs. The top row represents the early stage, and the bottom row represents the late stage. CFSE-labeled adoptively transferred CTLs are shown in green. Scale bars: 50 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.007">http://dx.doi.org/10.7554/eLife.14756.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.008</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Long-term and large-field imaging of the process by which Tregs formed an immunosuppressive ring.</title><p>CFP-B16 tumor is shown in blue (CFP), Tregs are shown in red (mRFP), and adoptively transferred CTLs are shown in green (CFSE, rarely observed). Top row: large-field images; scale bar: 500 µm. Bottom row: images of the region of interest; scale bar: 100 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.008">http://dx.doi.org/10.7554/eLife.14756.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig1-figsupp3-v2"/></fig></fig-group></p><p>To determine the reasons for the failure of adoptive CTLs, we detected the distribution of these cells in different organs of CFP-B16 tumor-bearing mice at an early stage (1–3 days after the adoptive transfer of CTLs) and a later stage (4–6 days after the adoptive transfer of CTLs). Adoptive CTLs stained with the fluorescent dye CFSE (5-(and-6)-carboxyfluorescein diacetate succinimidyl ester, CFDA SE) were intravenously transferred into tumor-bearing mice on the sixth day after the implantation of tumor cells, which we defined as Day 0. The distribution of the CTLs was assessed in vivo by fluorescence imaging of frozen tissue sections from the naïve lymph nodes (NLNs), tumor-draining lymph nodes (TDLNs), spleens and tumors. The data indicated that the CTLs primarily accumulated in the TDLNs but rarely accumulated in the tumors during either the early or the late stage (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p></sec><sec id="s2-2"><title>Tregs formed an ‘immunosuppressive ring’ around the solid tumor</title><p>To visualize the immune reaction in the tumor microenvironment under immunotherapy dynamically, we established a murine model of the multicolor-coded tumor microenvironment using fluorescent protein (FP) transgenic C57BL/6 mice with a skin-fold window chamber implanted with CFP-B16 tumor cells. Here, several types of FP transgenic C57BL/6 mice were used to represent the host immunocytes: Foxp3<sup>+</sup> regulatory T cells were labeled with red FP (mRFP), endogenous tumor-infiltrating lymphocytes were labeled with green FP (GFP), CD11c<sup>+</sup> dendritic cells were labeled with yellow FP (YFP), and tumor-infiltrating immunocytes (TIIs) were labeled with enhanced green FP (EGFP).</p><p>The intravital imaging data revealed that only a few CFSE-labeled adoptive CTLs infiltrated into the tumor area, regardless of an early or late stage post-adoptive CTL transfer (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Compared with the rare infiltration of adoptive CTLs, Tregs (<italic>Foxp3</italic>-mRFP cells) were clearly observed infiltrating the tumor microenvironment on Day 1, before they gradually accumulated at the edge of the tumor to form a ring on Day 5 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). This observation suggested that an ‘immunosuppressive ring’ formed by Tregs surrounded the solid tumor to prevent the recruitment of adoptive CTLs, as illustrated in the schematic diagram in <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</p></sec><sec id="s2-3"><title>CTX treatment eliminates Tregs, blocks the formation of the immunosuppressive ring, and accelerates the infiltration of adoptive CTLs into the tumor</title><p>To verify the immunosuppressive effect of Tregs on the infiltration of adoptive CTLs into the tumor areas, CTX (150 mg kg<sup>−1</sup>) was used to specifically abrogate Tregs on the fourth day after the implantation of CFP-B16 tumor cells. This CTX dose was selected on the basis of CFP-B16 tumor inhibition experiments with different CTX doses in immune-competent C57BL/6 mice and immune-deficient BALB/c nude mice. The results of these experiments showed that, compared with other CTX doses (50 mg kg<sup>−1</sup> and 100 mg kg<sup>−1</sup>) usually used in tumor immunotherapy, only the dose of 150 mg kg<sup>−1</sup> CTX controlled the CFP-B16 tumor growth successfully when CTX was used alone as well as when it was used in combination with ACT (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Furthermore, a tumor growth inhibition experiment performed on the BALB/c nude mice, confirmed that the effective anti-tumor effect of CTX at the dose of 150 mg kg<sup>−1</sup> is not due to its direct cytotoxicity, because no difference in the inhibition of tumor growth was observed between the PBS control group and the mice treated with different doses of CTX (50, 100 or 150 mg kg<sup>−1</sup>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). These results suggest that the efficacy of the 150 mg kg<sup>−1</sup> CTX treatment for CFP-B16 tumor in C57BL/6 mice depends on the enhanced anti-tumor immune response, and not on the direct cytotoxicity of the treatment.</p><p>Two days later, in-vitro-expanded and activated CTLs were intravenously transferred into the tumor-bearing mice; this day was defined as Day 0 (six days after tumor cells implantation). The CTX-ACT combined treatment significantly inhibited tumor growth compared with the ACT treatment alone, but produced results that were not significantly different from those produced by the CTX treatment alone (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The spatio-temporal changes in immunocytes in the tumor microenvironment were monitored on Days 1–7 using large-field confocal microscopy.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.009</object-id><label>Figure 2.</label><caption><title>Synergistic effect of CTX and the adoptive CTLs (ACT) on CFP-B16 tumor immunotherapy.</title><p>(<bold>A</bold>) Growth curves for the CFP-B16 tumors treated with ACT, CTX or CTX-ACT and the PBS control. The data are represented as the mean ± SEM tumor volume (n = 12–14, three independent experiments). ns: not significant, ***p&lt;0.001, (<xref ref-type="supplementary-material" rid="SD3-data">Figure 2—source data 1</xref>). (<bold>B</bold>) Intravital confocal fluorescence imaging of Tregs (red) at the tumor periphery (left panel), and immunohistochemistry (right panel) of the CFP-B16 tumor tissues after ACT (top row) or CTX-ACT (bottom row) treatment. Scale bars: 100 µm. The arrows indicate Tregs. (<bold>C</bold>) Long-term intravital imaging of the multicolor-coded tumor environment in CTX-ACT-treated mice. Red – Tregs (Foxp3-mRFP); green –CSFE-labeled CTLs; blue –CFP-B16 tumor. Top row: large-field images; scale bar: 500 µm. Bottom row: images from the region of interest in the top row; scale bar: 100 µm. The imaging data are representative of similar results from 3–5 mice in two independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.009">http://dx.doi.org/10.7554/eLife.14756.009</ext-link></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.14756.010</object-id><label>Figure 2—source data 1.</label><caption><title>Growth curves for the CFP-B16 tumors treated with ACT, CTX, CTX-ACT or PBS control.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.010">http://dx.doi.org/10.7554/eLife.14756.010</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig2-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.011</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Evaluation of the effect of different doses of CTX and CTX combined with ACT on CFP-B16 tumor growth in vivo.</title><p>(<bold>A</bold>,<bold>B</bold>) Growth curves for the CFP-B16 tumors in (<bold>A</bold>) C57BL/6 and (<bold>B</bold>) BALB/c nude mice treated with different doses of CTX (50, 100 or 150 mg kg<sup>−1</sup>), different doses of CTX (50, 100 or 150 mg kg<sup>−1</sup>) combined with ACT, and PBS control. The data are represented as the mean ± SEM tumor volume (n = 9–10, two independent experiments). ***p&lt;0.001, ns: not significant, (<xref ref-type="supplementary-material" rid="SD5-data">Figure 2—figure supplement 1—source data 1</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.011">http://dx.doi.org/10.7554/eLife.14756.011</ext-link></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.14756.012</object-id><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Growth curves for the CFP-B16 tumors in C57BL/6 and BALB/c nude mice treated with different doses of CTX, different doses of CTX combined with ACT treatment and PBS control.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.012">http://dx.doi.org/10.7554/eLife.14756.012</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig2-figsupp1-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.013</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Quantification of the intravital imaging of Tregs and adoptive CTLs in ACT- and CTX-ACT-treated mice.</title><p>(<bold>A</bold>) Density of Tregs and (B) adoptive CTLs were determined by counting the number of mRFP-Tregs and CFSE-labeled CTLs per mm<sup>2</sup> in the tumor area. The data are represented as the mean ± SEM (n = 10–12 fields, 0.40 mm<sup>2</sup> per field) from 3–5 mice in two independent experiments. ***p&lt;0.001, (<xref ref-type="supplementary-material" rid="SD5-data">Figure 2—figure supplement 2—source data 1</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.013">http://dx.doi.org/10.7554/eLife.14756.013</ext-link></p><p><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.14756.014</object-id><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Density of Tregs and adoptive CTLs in the tumor area.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.014">http://dx.doi.org/10.7554/eLife.14756.014</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig2-figsupp2-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig2-figsupp2-v2"/></fig></fig-group></p><p>First, we assessed whether the CTX treatment effectively depleted Tregs. Intravital imaging (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) demonstrated that without CTX treatment, the margin of the tumor was surrounded by a layer of Tregs on Day 5 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, top left corner). The CTX treatment successfully eliminated most of the Tregs in the tumor area and removed the ‘immunosuppressive ring’ formed by Tregs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, bottom left corner). These imaging results were further confirmed by immunohistochemical staining using the anti-Foxp3 antibody (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, right panel). In addition, the number of CFSE-labeled CTLs in the tumor area was clearly increased in CTX-ACT-treated mice, compared with that in mice received the ACT treatment alone (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, left panel, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>Next, long-term large-field intravital imaging revealed the entire immune reaction in the tumor microenvironment after CTX-ACT treatment, from the accumulation of adoptive CTLs to the destruction of the tumor (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These images showed that in the combined treatment, few adoptive CTLs infiltrated into the tumor microenvironment during the early stage (Days 1–3). Subsequently, the accumulation of CTLs increased significantly during the late stage (Days 4–6, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). By contrast, mRFP-Tregs were rarely observed regardless of the respective stage (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). The elimination of Tregs and the infiltration of CTLs resulted in large-scale tumor death consisting of tumors 'shrinking' from the outside and 'melting' from the inside (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, Days 5–6). This finding suggested that the infiltrating CTLs destroyed the solid tumor by applying two approaches: attacking the tumor cells at the periphery according to an 'outside-in' pattern and eliminating tumor cells at the parenchyma according to an 'inside-out' pattern. The anti-tumor effect of the adoptive CTLs peaked at Days 5–6. One day later (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, Day 7), the number of adoptive CTLs decreased rapidly in the tumor area because of the death or dysfunction of CTLs, leading to tumor regrowth.</p></sec><sec id="s2-4"><title>Four stages of adoptive CTLs migration in the tumor microenvironment after CTX-ACT treatment</title><p>The migration of adoptive CTLs is the crucial step in accelerating the penetration of CTLs into the solid tumors. To understand the migratory behavior of the adoptive CTLs in the tumor microenvironment, we obtained dynamic information about the adoptive CTLs using confocal laser scanning microscopy (CLSM) from Day 1 to Day 6 after the CTX-ACT treatment (<xref ref-type="fig" rid="fig3">Figure 3A–D</xref>). Subsequently, we quantified the motility of the adoptive CTLs in detail over four stages. Three parameters were used to describe the motility properties of the CTLs in vivo (<xref ref-type="fig" rid="fig3">Figure 3F–H</xref>): the mean velocity, which represents the migratory speed; the confinement ratio, which indicates the ratio of the maximum displacement of each cell from its path length within a given time (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Cahalan and Parker, 2008</xref>); and the arrest coefficient, which denotes the percentage of time that each cell remained arrested (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>).<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.015</object-id><label>Figure 3.</label><caption><title>Migratory behavior of the adoptive CTLs in the tumor microenvironment of mice treated with CTX-ACT.</title><p>(<bold>A</bold>–<bold>D</bold>) Time-lapse images of CTLs with time-coded motion trajectories (color scale represents the duration). (<bold>A</bold>,<bold>C</bold>) Images of CTLs (green) at the periphery (near the blue area, <bold>A</bold>) or in the parenchyma (in the blue area, <bold>C</bold>) of the CFP-B16 tumors on different days after CTX-ACT treatment. Scale bar: 100 µm. (<bold>B</bold>,<bold>D</bold>) Trajectories of the individual CTLs at the periphery or in the parenchyma were plotted following the alignment of their starting positions. (<bold>E</bold>) Random walking analysis of the adoptive CTLs. Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs at the periphery of (top) or in the parenchyma (bottom) on different days, (<xref ref-type="supplementary-material" rid="SD6-data">Figure 3—source data 1</xref>–<xref ref-type="supplementary-material" rid="SD14-data">9</xref>). (<bold>F</bold>–<bold>H</bold>) Scatter plots of (<bold>F</bold>) the mean velocity, (<bold>G</bold>) the confinement ratio, and (<bold>H</bold>) the arrest coefficient of the CTLs at the tumor periphery or in the tumor parenchyma on different days after CTX-ACT treatment. Each data point represents a single cell, and the red bars indicate mean values. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns – not significant, (<xref ref-type="supplementary-material" rid="SD15-data">Figure 3—source data 10</xref>). The data from 4–6 mice in three independent experiments were pooled.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.015">http://dx.doi.org/10.7554/eLife.14756.015</ext-link></p><p><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.14756.016</object-id><label>Figure 3—source data 1.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs at the tumor periphery on Day 1.</title><p>Data listed in the excel files are displacements. Displacement is a function of time. Each column in the excel files lists displacements corresponding to one time. The time values are 0.5 min, 1 min, 1.5 min, and so on, in turn.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.016">http://dx.doi.org/10.7554/eLife.14756.016</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data1-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD7-data"><object-id pub-id-type="doi">10.7554/eLife.14756.017</object-id><label>Figure 3—source data 2.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs at the tumor periphery on Day 3.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.017">http://dx.doi.org/10.7554/eLife.14756.017</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data2-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD8-data"><object-id pub-id-type="doi">10.7554/eLife.14756.018</object-id><label>Figure 3—source data 3.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs at the tumor periphery on Day 5.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.018">http://dx.doi.org/10.7554/eLife.14756.018</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data3-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD9-data"><object-id pub-id-type="doi">10.7554/eLife.14756.019</object-id><label>Figure 3—source data 4.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs at the tumor periphery on Day 6.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.019">http://dx.doi.org/10.7554/eLife.14756.019</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data4-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD10-data"><object-id pub-id-type="doi">10.7554/eLife.14756.020</object-id><label>Figure 3—source data 5.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs in the tumor parenchyma on Day 3.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.020">http://dx.doi.org/10.7554/eLife.14756.020</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data5-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD11-data"><object-id pub-id-type="doi">10.7554/eLife.14756.021</object-id><label>Figure 3—source data 6.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs in the tumor parenchyma on Day 5.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.021">http://dx.doi.org/10.7554/eLife.14756.021</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data6-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD12-data"><object-id pub-id-type="doi">10.7554/eLife.14756.022</object-id><label>Figure 3—source data 7.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the CTLs in the tumor parenchyma on Day 6.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.022">http://dx.doi.org/10.7554/eLife.14756.022</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig3-data7-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD13-data"><object-id pub-id-type="doi">10.7554/eLife.14756.023</object-id><label>Figure 3—source data 8.</label><caption><title>Linear fitting results of MD (mean displacement) of adoptive CTLs at the tumor periphery on Day 1, Day 3, Day 5 and Day 6.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.023">http://dx.doi.org/10.7554/eLife.14756.023</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-14756-fig3-data8-v2.docx"/></supplementary-material></p><p><supplementary-material id="SD14-data"><object-id pub-id-type="doi">10.7554/eLife.14756.024</object-id><label>Figure 3—source data 9.</label><caption><title>Linear fitting results of MD (mean displacement) of adoptive CTLs in the tumor parenchyma on Day 3, Day 5 and Day 6.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.024">http://dx.doi.org/10.7554/eLife.14756.024</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-14756-fig3-data9-v2.docx"/></supplementary-material></p><p><supplementary-material id="SD15-data"><object-id pub-id-type="doi">10.7554/eLife.14756.025</object-id><label>Figure 3—source data 10.</label><caption><title>Scatter plots of the mean velocity, confinement ratio, and arrest coefficient of the adoptive CTLs at the tumor periphery or in the tumor parenchyma on different days.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.025">http://dx.doi.org/10.7554/eLife.14756.025</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig3-data10-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig3-v2"/></fig></p><p>The first stage corresponds to Days 1–2. During this stage, a number of adoptive CTLs migrated to the tumor periphery (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, Day 1) with a mean velocity of 3.23 ± 2.18 µm min<sup>−1</sup> (n = 80 cells from 4–5 mice, <xref ref-type="fig" rid="fig3">Figure 3F</xref>) and only a few CTLs infiltrated into the tumor parenchyma (<xref ref-type="other" rid="media1">Video 1</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media1" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media1.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.026</object-id><label>Video 1.</label><caption><title>In vivo sequential imaging of adoptive CTLs at the periphery and in the parenchyma of CFP-B16 tumors on Day 1 (after CTX-ACT treatment).</title><p>The 3D time-lapse images were acquired as a 30 μm z-stack. Adoptively transferred CTLs are shown in green (CFSE-labeled), and the B16 tumor cells are shown in blue (CFP). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.026">http://dx.doi.org/10.7554/eLife.14756.026</ext-link></p></caption></media></p><p>The second stage corresponds to Days 3–4. During this stage, adoptive CTLs accumulated at the periphery of the tumor (mean velocity – 3.13 ± 2.43 µm min<sup>−1</sup>, confinement ratio – 0.57 ± 0.29, and arrest coefficient – 48 ± 36%, n = 305 cells; <xref ref-type="fig" rid="fig3">Figure 3A,F–H</xref>, Day 3) and their motility was similar to that at Day 1. Nevertheless, a few of adoptive CTLs were able to infiltrate into the tumor parenchyma, and remained confined with constrained trajectories (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>) and slow speed (mean velocity – 0.87 ± 0.28 µm min<sup>−1</sup>, confinement ratio – 0.32 ± 0.21, and arrest coefficient – 91 ± 8%; n = 118 cells; <xref ref-type="fig" rid="fig3">Figure 3F–H</xref>), suggesting that these CTLs formed stable interactions with neighboring tumor cells (<xref ref-type="other" rid="media2">Video 2</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media2" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media2.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.027</object-id><label>Video 2.</label><caption><title>In vivo sequential imaging of adoptive CTLs at the periphery and in the parenchyma of CFP-B16 tumors on Day 3.</title><p>The 3D time-lapse images were acquired as a 30 μm z-stack. Adoptively transferred CTLs are shown in green (CFSE-labeled), and the B16 tumor cells are shown in blue (CFP). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.027">http://dx.doi.org/10.7554/eLife.14756.027</ext-link></p></caption></media></p><p>During the third stage (Day 5), a larger number of adoptive CTLs migrated to the tumor periphery and their mean velocity dramatically increased to 5.79 ± 3.12 µm min<sup>−1</sup> (n = 428 cells), which was much faster than the mean velocities calculated during the first two stages (p&lt;0.001; <xref ref-type="fig" rid="fig3">Figure 3F</xref>). Consistently, the migration trajectories at this stage were less confined (confinement ratio: 0.67 ± 0.26; <xref ref-type="fig" rid="fig3">Figure 3B,G</xref>), and the arrest coefficient decreased to 22 ± 30% (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). The CTLs in the deep tumor parenchyma also displayed a trend toward greater speed with a marked increase in their mean velocity to 3.22 ± 2.58 µm min<sup>−1</sup> (n = 193 cells; <xref ref-type="fig" rid="fig3">Figure 3F</xref>), less confined trajectories (confinement ratio – 0.60 ± 0.25; <xref ref-type="fig" rid="fig3">Figure 3B,G</xref>) and a decrease in the arrest coefficient (50 ± 39%; <xref ref-type="fig" rid="fig3">Figure 3H</xref>). The changes in the migratory behavior of the CTLs in both tumor periphery and parenchyma were consistent with the observed tumor destruction (<xref ref-type="fig" rid="fig2">Figures 2C</xref> and <xref ref-type="fig" rid="fig3">3C</xref>, <xref ref-type="other" rid="media3">Video 3</xref>), indicating that when most tumor cells were killed, the adoptive CTLs resumed their high-speed movement to search for new targets.<media content-type="glencoe play-in-place height-250 width-310" id="media3" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media3.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.028</object-id><label>Video 3.</label><caption><title>In vivo sequential imaging of adoptive CTLs at the periphery and in the parenchyma of CFP-B16 tumors on Day 5.</title><p>The 3D time-lapse images were acquired as a 30 μm z-stack. Adoptively transferred CTLs are shown in green (CFSE-labeled), and the B16 tumor cells are shown in blue (CFP). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.028">http://dx.doi.org/10.7554/eLife.14756.028</ext-link></p></caption></media></p><p>During the fourth stage (Day 6), the motility of CTLs near the tumor periphery remained high (mean velocity – 5.89 ± 3.9 µm min<sup>−1</sup>, confinement ratio – 0.69 ± 0.24, and arrest coefficient – 26 ± 34%; n = 147 cells; <xref ref-type="fig" rid="fig3">Figure 3F–H</xref>). By contrast, the motility of CTLs in the parenchyma significantly decreased as evidenced by their more confined trajectories and an obvious increase in the arrest coefficient (mean velocity – 0.86 ± 1.49 µm min<sup>−1</sup>, confinement ratio – 0.46 ± 0.22, and arrest coefficient – 88 ± 29%; <xref ref-type="fig" rid="fig3">Figure 3F–H</xref>). The decreased number and motility of the CTLs and tumor regrowth suggested that the adoptive CTLs were dysfunctional or died during this stage (<xref ref-type="other" rid="media4">Video 4</xref>). The mean displacement analysis revealed that all of the adoptive CTLs in both the tumor periphery and the tumor parenchyma displayed random walking during different stages (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media4" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media4.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.029</object-id><label>Video 4.</label><caption><title>In vivo sequential imaging of adoptive CTLs at the periphery and in the parenchyma of CFP-B16 tumors on Day 6.</title><p>The 3D time-lapse images were acquired as a 30 μm z-stack. Adoptively transferred CTLs are shown in green (CFSE-labeled), and the B16 tumor cells are shown in blue (CFP). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.029">http://dx.doi.org/10.7554/eLife.14756.029</ext-link></p></caption></media></p><p>These data suggested that the migratory behavior of adoptive CTLs in the tumor areas at different stages is correlated to their anti-tumor efficacy. The dysfunction and death of adoptive CTLs and tumor regrowth during the fourth stage suggested that a subsequent round of CTX-ACT combined treatment is required to maintain the anti-tumor immune activation.</p></sec><sec id="s2-5"><title>CTX-ACT treatment decreases total endogenous T cells but retains activated endogenous CTLs in the tumor microenvironment</title><p>Next, we studied the dynamic behavior of endogenous CTLs in the tumor area. Here, we used <italic>Cxcr6<sup>+/gfp</sup></italic> transgenic mice that carried the CXCR6 sequence on one allele but had the GFP gene replacing the <italic>Cxcr6</italic> coding region on the other allele, in which GFP cells with the CD8<sup>+</sup> marker represent endogenous CTLs (<xref ref-type="bibr" rid="bib57">Unutmaz et al., 2000</xref>; <xref ref-type="bibr" rid="bib50">Ruocco et al., 2012</xref>).</p><p>First, the ex vivo analysis of endogenous GFP cells in the CFP-B16 tumors of mice treated with PBS, ACT, CTX, and CTX-ACT on Day 5 (11 days after implantation of CFP-B16 tumor cells) was performed by flow cytometry. The data showed that the endogenous GFP cells in the tumors decreased after CTX-ACT treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). Importantly, most of the GFP cells in the tumors of the CTX-ACT-treated mice were CD8<sup>+</sup> CTLs with expression of the activation marker CD69 (more than 60%, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). These results suggest that the CTX-ACT combined treatment decreased the endogenous T cells but selectively retained the activated endogenous CD8<sup>+</sup> CTLs in the tumors.</p><p>In order to distinguish adoptive and endogenous CTLs by intravital imaging, the adoptive CTLs were labeled with the red fluorescent dye CMTPX and then transferred into <italic>Cxcr6<sup>+/gfp</sup></italic> transgenic mice with CFP-B16 tumor cells implanted into the window chamber on Day 0 (six days after tumor implantation). The intravital imaging was performed on Day 5 (five days after adoptive transfer of CTLs) because tumor elimination reached its peak in the CTX-ACT-treated mice on this day. Intravital imaging showed that the number of endogenous GFP T cells in the tumor area of CTX-ACT-treated mice was much smaller than that in ACT-treated mice (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). The analysis of the migratory behavior of the endogenous T cells showed that, compared with the ACT group, the motility of the endogenous GFP T cells in the tumor areas of the CTX-ACT group was significantly decreased (<xref ref-type="other" rid="media5">Video 5</xref>), with more confined trajectories and a significantly increased arrest coefficient (mean velocity – 3.80 ± 2.56 µm min<sup>−1</sup> in the CTX-ACT group versus 4.6 ± 2.0 µm min<sup>−1</sup> in the ACT group; confinement ratio – 0.47 ± 0.26 in the CTX-ACT group versus 0.60 ± 0.25 in the ACT group; and arrest coefficient – 43 ± 35% in the CTX-ACT group versus 25 ± 26% in the ACT group; <xref ref-type="fig" rid="fig4">Figure 4C–F</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.030</object-id><label>Figure 4.</label><caption><title>Migratory behavior of endogenous CTLs in the tumor microenvironment of mice treated with ACT and CTX-ACT on Day 5.</title><p>(<bold>A</bold>) In vivo time-lapse images of the endogenous GFP T cells (green) and adoptive CTLs (red) in the CFP-B16 tumor area (blue). Mice were treated with ACT or CTX-ACT. Scale bar: 100 μm. (<bold>B</bold>) Quantification of endogenous GFP T cells in the differently treated groups on Day 5. Results are represented as the mean ± SEM (n = 11–19 fields, 0.40 mm<sup>2</sup> per field) from three mice per group. ***p&lt;0.001 (<xref ref-type="supplementary-material" rid="SD16-data">Figure 4—source data 1</xref>). (<bold>C</bold>) Trajectories of GFP T cells in the differently treated groups were plotted following the alignment of their starting positions. (<bold>D</bold>–<bold>F</bold>) Scatter plots of (<bold>D</bold>) the mean velocity, (<bold>E</bold>) the confinement ratio, and (<bold>F</bold>) the arrest coefficient of the GFP T cells in tumor areas in the differently treated groups on Day 5. Each data point represents a single cell, and the red bars indicate mean values. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns: not significant (<xref ref-type="supplementary-material" rid="SD17-data">Figure 4—source data 2</xref>). The data from 3–5 mice in two independent experiments were pooled.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.030">http://dx.doi.org/10.7554/eLife.14756.030</ext-link></p><p><supplementary-material id="SD16-data"><object-id pub-id-type="doi">10.7554/eLife.14756.031</object-id><label>Figure 4—source data 1.</label><caption><title>Quantification of endogenous GFP T cells in the differently treated groups on Day 5.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.031">http://dx.doi.org/10.7554/eLife.14756.031</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig4-data1-v2.pzf"/></supplementary-material></p><p><supplementary-material id="SD17-data"><object-id pub-id-type="doi">10.7554/eLife.14756.032</object-id><label>Figure 4—source data 2.</label><caption><title>Scatter plots of the mean velocity, confinement ratio, and arrest coefficient of the GFP T cells in tumor areas in the differently treated groups on Day 5.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.032">http://dx.doi.org/10.7554/eLife.14756.032</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig4-data2-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.033</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of GFP cells in differently treated <italic>Cxcr6<sup>+/gfp</sup></italic> mice.</title><p>(<bold>A</bold>) Ex vivo analysis and characterization of the GFP cells in the tumors of <italic>Cxcr6<sup>+/gfp</sup></italic> mice that were treated differently. (<bold>B</bold>) Percentage of GFP cells in the tumors of mice following the different treatments. (<bold>C</bold>) Percentage of CD8<sup>+</sup>CD69<sup>+</sup> CTLs in the GFP cells from (<bold>B</bold>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.033">http://dx.doi.org/10.7554/eLife.14756.033</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig4-figsupp1-v2"/></fig></fig-group><media content-type="glencoe play-in-place height-250 width-310" id="media5" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media5.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.034</object-id><label>Video 5.</label><caption><title>In vivo sequential imaging of endogenous T cells and adoptive CTLs in CFP-B16 tumor areas in mice exposed to ACT and CTX-ACT combined treatments on Day 5.</title><p>Time-lapse images were collected for 15 min. Endogenous T cells are shown in green (GFP labeled), adoptive CTLs are shown in red (CMTPX labeled) and the B16 tumor cells are shown in blue (CFP labeled). Scale bar: 100 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.034">http://dx.doi.org/10.7554/eLife.14756.034</ext-link></p></caption></media></p><p>Both ex vivo characterization experiments and intravital imaging suggested that the CTX-ACT combined treatment deleted most of the endogenous T cells but retained the activated endogenous CTLs in the tumor area. The activated endogenous CTLs arrested in the tumor area for a long time and built stable, long-lasting interactions with the tumor cells to kill them efficiently.</p></sec><sec id="s2-6"><title>CTX-ACT treatment elicits the transient activation of endogenous TIIs</title><p>Next, we used EGFP-transgenic C57BL/6 mice to observe the activated endogenous immunocytes in the tumor areas. CFP-B16 tumor cells were implanted into EGFP mice, in which all of the nucleated cells expressed EGFP and most of the mobile cells in vivo were immunocytes. Using a multi-photon excitation microscope, the tumor microenvironments of the CFP-B16 tumors and TIIs were continuously observed through a skin-fold window chamber from the day prior to the adoptive transfer of CTLs (Day 0–4, <xref ref-type="fig" rid="fig5">Figure 5A,B</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.035</object-id><label>Figure 5.</label><caption><title>Migratory behavior of endogenous tumor-infiltrating immunocytes (TIIs) induced by the CTX-ACT treatment.</title><p>(<bold>A</bold>) Experimental procedure for long-term intravital imaging of TIIs in the tumor microenvironment. (<bold>B</bold>) In vivo time-lapse images of EGFP TIIs (green) in the CFP-B16 tumor area (blue) from Day 0 to Day 4 after CTX-ACT treatment. Green arrows represent TIIs displacement, and blue areas represent CFP-B16 tumors. Scale bar: 100 µm. (<bold>C</bold>) Trajectories of individual TIIs on different days were plotted following the alignment of their starting positions. (<bold>D</bold>–<bold>F</bold>) Scatter plots of the (<bold>D</bold>) mean velocity, (<bold>E</bold>) confinement ratio, and (<bold>F</bold>) arrest coefficient of EGFP TIIs in tumor areas on different days. Each data point represents a single cell, and the red bars indicate mean values. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns, not significant, (<xref ref-type="supplementary-material" rid="SD18-data">Figure 5—source data 1</xref>). (<bold>G</bold>) Random walking analysis of the TIIs on different days. Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs, (<xref ref-type="supplementary-material" rid="SD19-data">Figure 5—source data 2</xref>–<xref ref-type="supplementary-material" rid="SD24-data">7</xref>). The data from 4–7 mice in three independent experiments were pooled.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.035">http://dx.doi.org/10.7554/eLife.14756.035</ext-link></p><p><supplementary-material id="SD18-data"><object-id pub-id-type="doi">10.7554/eLife.14756.036</object-id><label>Figure 5—source data 1.</label><caption><title>Scatter plots of the mean velocity, confinement ratio, and arrest coefficient of EGFP TIIs in tumor areas on different days.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.036">http://dx.doi.org/10.7554/eLife.14756.036</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig5-data1-v2.pzf"/></supplementary-material></p><p><supplementary-material id="SD19-data"><object-id pub-id-type="doi">10.7554/eLife.14756.037</object-id><label>Figure 5—source data 2.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs on Day 0. </title><p>Data listed in the excel files are displacements. Displacement is a function of time. Each column in the excel files lists displacements corresponding to one time. The time values are 0.5 min, 1 min, 1.5 min, and so on, in turn.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.037">http://dx.doi.org/10.7554/eLife.14756.037</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig5-data2-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD20-data"><object-id pub-id-type="doi">10.7554/eLife.14756.038</object-id><label>Figure 5—source data 3.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs on Day 1.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.038">http://dx.doi.org/10.7554/eLife.14756.038</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig5-data3-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD21-data"><object-id pub-id-type="doi">10.7554/eLife.14756.039</object-id><label>Figure 5—source data 4.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs on Day 2.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.039">http://dx.doi.org/10.7554/eLife.14756.039</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig5-data4-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD22-data"><object-id pub-id-type="doi">10.7554/eLife.14756.040</object-id><label>Figure 5—source data 5.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs on Day 3.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.040">http://dx.doi.org/10.7554/eLife.14756.040</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig5-data5-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD23-data"><object-id pub-id-type="doi">10.7554/eLife.14756.041</object-id><label>Figure 5—source data 6.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs on Day 4.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.041">http://dx.doi.org/10.7554/eLife.14756.041</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig5-data6-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD24-data"><object-id pub-id-type="doi">10.7554/eLife.14756.042</object-id><label>Figure 5—source data 7.</label><caption><title>Linear fitting results of MD (Mean displacement) of TIIs at tumor areas on Day 0–Day 4.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.042">http://dx.doi.org/10.7554/eLife.14756.042</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-14756-fig5-data7-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig5-v2"/></fig></p><p>On Day 1, the endogenous TIIs in the CTX-ACT-treated mice migrated rapidly toward the tumor parenchyma (mean velocity – 4.92 ± 2.80 µm min<sup>−1</sup>; n = 435 cells). The velocity on Day 1 (24 hr after CTX-ACT treatment, <xref ref-type="fig" rid="fig5">Figure 5B–D</xref>, <xref ref-type="other" rid="media6">Video 6</xref>) was approximately 2.4-fold faster than that on Day 0 (2.07 ± 2.18 µm min<sup>−1</sup>, n = 477 cells; <xref ref-type="fig" rid="fig5">Figure 5D</xref>). Consistently, the TIIs on Day 1 displayed more expanded migration trajectories (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and less arrest (confinement ratio – 0.66 ± 0.25 on Day 1, 0.43 ± 0.26 on Day 0; arrest coefficient – 21 ± 21% on Day 1, 68 ± 37% on Day 0, <xref ref-type="fig" rid="fig5">Figure 5E, F</xref>).<media content-type="glencoe play-in-place height-250 width-310" id="media6" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media6.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.043</object-id><label>Video 6.</label><caption><title>In vivo sequential imaging of endogenous TIIs at the periphery of the CFP-B16 tumors on different days following treatment with CTX and ACT.</title><p>Time-lapse images were collected for 10 or 15 min. Endogenous TIIs are shown in green (EGFP), and the B16 tumor cells are shown in blue (CFP). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.043">http://dx.doi.org/10.7554/eLife.14756.043</ext-link></p></caption></media></p><p>On Day 2, the motility of the endogenous TIIs decelerated markedly (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>), demonstrating a decreased mean velocity (1.51 ± 1.78 µm min<sup>−1</sup>; n = 136 cells) and confinement ratio (0.48 ± 0.29) and an increased arrest coefficient (75 ± 36%, <xref ref-type="fig" rid="fig5">Figure 5D–F</xref>). On Day 3 and Day 4, the speed of the TIIs further decreased (0.72 ± 0.31 µm min<sup>−1</sup>, n = 164 cells; 0.62 ± 0.72 µm min<sup>−1</sup>, n = 124 cells, respectively), and all other motility parameters of the TIIs differed from those on Day 2 (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref>). The mean displacement of the TIIs on different days was consistent with random walking (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Thus, a transient increase in the motility of the endogenous TIIs was induced within 24 hr after the CTX-ACT treatment. These findings indicate that Day 1 is a key point in time for the activation of endogenous anti-tumor immune reactions in response to the CTX-ACT combined treatment. We speculated that the tumor destruction was caused by both adoptive CTLs and endogenous TIIs.</p></sec><sec id="s2-7"><title>Both CTX and ACT treatments are the essential factors for the chemotaxis and recruitment of TIIs into the tumor parenchyma</title><p>To further investigate the role of CTX-ACT treatment in the activation of endogenous TIIs, we analyzed the movement of TIIs in the tumor microenvironment of mice exposed to different treatments on the same day (Day 1 after the CTX-ACT treatment and seven days after tumor implantation). Analysis of the imaging data and migratory path indicated that the chemotaxis of the endogenous TIIs toward the tumor parenchyma was elicited only by the CTX-ACT treatment (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>, <xref ref-type="other" rid="media7">Video 7</xref>), which caused the TII movement to display long and linear trajectories (confinement ratio – 0.66 ± 0.25, <xref ref-type="fig" rid="fig6">Figure 6B,D</xref>). Compared with those in the CTX-ACT treatment group, the directions of TII movement in the ACT and PBS groups were disordered with confined trajectories (confinement ratio – 0.57 ± 0.27 in the ACT group and 0.47 ± 0.24 in the PBS group, <xref ref-type="fig" rid="fig6">Figure 6A,B and D</xref>). Although the trajectories of the TIIs in the CTX group were less confined with a high confinement ratio (0.63 ± 0.25), the directional movement of the TIIs was disordered (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>).<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.044</object-id><label>Figure 6.</label><caption><title>Migratory behavior of the TIIs following different treatments.</title><p>(<bold>A</bold>) In vivo time-lapse images of the EGFP TIIs in the CFP-B16 tumor area on Day 1. Mice were treated with ACT, CTX, CTX-ACT or PBS control. Green arrows represent TIIs displacement, and blue areas represent CFP-B16 tumors. Scale bar: 100 µm. (<bold>B</bold>) The trajectories of individual EGFP TIIs in different treated groups were plotted following the alignment of their starting positions. (<bold>C</bold>–<bold>E</bold>) Scatter plots of the (<bold>C</bold>) mean velocity, (<bold>D</bold>) confinement ratio, and (<bold>E</bold>) arrest coefficient of the EGFP TIIs in the differently treated groups. Each data point represents a single cell, and the red bars indicate mean values. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns, not significant (<xref ref-type="supplementary-material" rid="SD25-data">Figure 6—source data 1</xref>). (<bold>F</bold>) Random walking analysis of the TIIs in the different groups. Mean displacement (μm) versus the square root of time (min<sup>1/2</sup>) of TIIs in different treatment groups ( <xref ref-type="supplementary-material" rid="SD26-data">Figure 6—source data 2</xref>–<xref ref-type="supplementary-material" rid="SD30-data">6</xref>). The data from 12–15 mice in three independent experiments were pooled.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.044">http://dx.doi.org/10.7554/eLife.14756.044</ext-link></p><p><supplementary-material id="SD25-data"><object-id pub-id-type="doi">10.7554/eLife.14756.045</object-id><label>Figure 6—source data 1.</label><caption><title>Scatter plots of the mean velocity, confinement ratio, and arrest coefficient of the EGFP TIIs in the different treatment groups.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.045">http://dx.doi.org/10.7554/eLife.14756.045</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig6-data1-v2.pzf"/></supplementary-material></p><p><supplementary-material id="SD26-data"><object-id pub-id-type="doi">10.7554/eLife.14756.046</object-id><label>Figure 6—source data 2.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs in the PBS group. </title><p>Data listed in the excel files are displacements. Displacement is a function of time. Each column in the excel files lists displacements corresponding to one time. The time values are 0.5 min, 1 min, 1.5 min, and so on, in turn. </p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.046">http://dx.doi.org/10.7554/eLife.14756.046</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig6-data2-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD27-data"><object-id pub-id-type="doi">10.7554/eLife.14756.047</object-id><label>Figure 6—source data 3.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs in the ACT group.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.047">http://dx.doi.org/10.7554/eLife.14756.047</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig6-data3-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD28-data"><object-id pub-id-type="doi">10.7554/eLife.14756.048</object-id><label>Figure 6—source data 4.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs in the CTX group.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.048">http://dx.doi.org/10.7554/eLife.14756.048</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig6-data4-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD29-data"><object-id pub-id-type="doi">10.7554/eLife.14756.049</object-id><label>Figure 6—source data 5.</label><caption><title>Mean displacement (μm) versus the square root of the time (min<sup>1/2</sup>) of the TIIs in the CTX-ACT group.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.049">http://dx.doi.org/10.7554/eLife.14756.049</ext-link></p></caption><media mime-subtype="excel" mimetype="application" xlink:href="elife-14756-fig6-data5-v2.xls"/></supplementary-material></p><p><supplementary-material id="SD30-data"><object-id pub-id-type="doi">10.7554/eLife.14756.050</object-id><label>Figure 6—source data 6.</label><caption><title>Linear fitting results of MD (Mean displacement) of TIIs at tumor areas in the different treatment groups on Day 1.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.050">http://dx.doi.org/10.7554/eLife.14756.050</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-14756-fig6-data6-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.14756.051</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Phenotype of EGFP TIIs in CFP-B16 tumors of mice following different treatments.</title><p>(<bold>A</bold>) Representative tumor sections stained with CD3, Ly6G and F4/80. Most of the EGFP TIIs at the tumor periphery were Ly6G<sup>+</sup> and F4/80<sup>+</sup>. Scale bar: 50 μm. (<bold>B</bold>) Histopathology of HE-stained tumor sections from tumor-bearing mice exposed to different treatments. Black arrows indicate neutrophils. Scale bar: 50 μm. (<bold>C</bold>) Percentage of neutrophils among TIIs at the periphery of the tumors in mice that received different treatments. The data are represented as the mean ± SEM (n = 14–20 fields) results from three mice per group. *p&lt;0.05, **p&lt;0.01, (<xref ref-type="supplementary-material" rid="SD31-data">Figure 6—figure supplement 1—source data 1</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.051">http://dx.doi.org/10.7554/eLife.14756.051</ext-link></p><p><supplementary-material id="SD31-data"><object-id pub-id-type="doi">10.7554/eLife.14756.052</object-id><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Percentage of neutrophils among TIIs at the periphery of the tumors in mice that received different treatments.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.052">http://dx.doi.org/10.7554/eLife.14756.052</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig6-figsupp1-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig6-figsupp1-v2"/></fig></fig-group><media content-type="glencoe play-in-place height-250 width-310" id="media7" mime-subtype="mp4" mimetype="video" xlink:href="elife-14756-media7.mp4"><object-id pub-id-type="doi">10.7554/eLife.14756.053</object-id><label>Video 7.</label><caption><title>In vivo sequential imaging of endogenous TIIs at the periphery of the CFP-B16 tumors on Day 1 in mice exposed to different treatments.</title><p>Time-lapse images were collected for a duration of 10 or 15 min. Mice were mock-treated (with PBS) or treated with CTX, ACT, or CTX-ACT as indicated. Endogenous TIIs are shown in green (EGFP-labeled) and the B16 tumor cells are shown in blue (CFP-labeled). Scale bar: 70 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.053">http://dx.doi.org/10.7554/eLife.14756.053</ext-link></p></caption></media></p><p>The endogenous TIIs in the CTX-ACT treatment group displayed the greatest motility with the fastest mean velocity (4.92 ± 2.80 µm min<sup>−1</sup>; <xref ref-type="fig" rid="fig6">Figure 6C</xref>) and the lowest arrest coefficient (21 ± 21%, <xref ref-type="fig" rid="fig6">Figure 6E</xref>). The TIIs in both the ACT and PBS groups displayed similarly low mean velocities and high arrest coefficients (2.51 ± 2.53 µm min<sup>−1</sup> and 61 ± 40% in the ACT group, respectively; 2.18 ± 2.31 µm min<sup>−1</sup> and 66 ± 39% in the PBS group, respectively; <xref ref-type="fig" rid="fig6">Figure 6C,E</xref>). The motility of the TIIs in the CTX group was higher than that in the ACT or PBS groups but was still lower than that in the CTX-ACT group (mean velocity – 4.1 ± 3.1 µm min<sup>−1</sup>; arrest coefficient – 39 ± 38%, <xref ref-type="fig" rid="fig6">Figure 6C,E</xref>). The mean displacement of TIIs in the different groups was consistent with random walking except for that in the CTX group, where the TIIs displayed slightly constrained motility (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Among all of these groups, only the CTX-ACT treatment group exhibited the movement of TIIs toward the tumor parenchyma with high motility and expanded trajectories. These findings indicate that the CTX-ACT treatment had a synergistic effect on the activation of endogenous TIIs, which in return accelerated the anti-tumor effects of the adoptive CTLs.</p><p>Immunofluorescence analysis of the frozen tumor sections showed that most of the tumor-surrounding EGFP cells were Ly6G<sup>+</sup> cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Hematoxylin and eosin (HE) staining further confirmed that more than 50% of the immunocytes surrounding the tumors were neutrophils (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>). These results indicated that the CTX-ACT treatment triggered the activity of endogenous neutrophils in the anti-tumor immune response rapidly, just 24 hr after the CTX-ACT treatment (Day 1).</p></sec><sec id="s2-8"><title>CTX-ACT treatment accelerates the infiltration of mature DCs into the tumor areas</title><p>DCs also played a key role in activating anti-tumor immune responses. To investigate whether the CTX-ACT treatment accelerated the infiltration of DCs into the tumors, we observed the tumor microenvironment using large-field microscopy. The imaging data showed that many DCs infiltrated into the tumor areas of the CTX-ACT-treated mice on Day 3 (three days after CTX-ACT treatment, <xref ref-type="fig" rid="fig7">Figure 7A</xref>). The density of the DCs in the CTX-ACT group increased by 3.6-fold compared with that in the PBS group, by 2.0-fold compared with that in the CTL group and by 1.6-fold compared with that in the CTX group (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Immunofluorescence analysis of the frozen tumor sections from CTX-ACT-treated mice revealed that certain YFP-labeled DCs displayed an mature phenotype characterized by the expression of MHC-II and CD86, indicating that some mature DCs were present in the tumor areas (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). This finding suggests that the CTX-ACT treatment promotes the infiltration of DCs (some of them were mature) to the tumor areas to further enhance the anti-tumor effects.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.054</object-id><label>Figure 7.</label><caption><title>Intravital imaging of DCs infiltrating into the tumor areas of the mice following different treatments.</title><p>(<bold>A</bold>) Large-field intravital imaging of DCs (green) and Tregs (red) in the CFP-B16 tumor area (blue) on Day 3. Top row: large-field images; scale bar 500 µm. Bottom row: images of the region of interest from the top row; scale bar 100 µm. (<bold>B</bold>) Density of DCs in the tumor areas in the different treatment groups. The data are represented as the mean ± SEM (n = 10–14 fields, 12 mm<sup>2</sup> per field (large-field images) or 0.40 mm<sup>2</sup> per field) from three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns, not significant (<xref ref-type="supplementary-material" rid="SD32-data">Figure 7—source data 1</xref>). (<bold>C</bold>) Representative images of mature DCs in tumor sections were immunofluorescently labeled to detect MHC II (top row) and CD86 (bottom row). Scale bar: 40 µm. Inserts are magnifications of the regions indicated with arrows. Scale bar: 15 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.054">http://dx.doi.org/10.7554/eLife.14756.054</ext-link></p><p><supplementary-material id="SD32-data"><object-id pub-id-type="doi">10.7554/eLife.14756.055</object-id><label>Figure 7—source data 1.</label><caption><title>Density of DCs in the tumor areas in the different treatment groups.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.055">http://dx.doi.org/10.7554/eLife.14756.055</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig7-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig7-v2"/></fig></p></sec><sec id="s2-9"><title>Design of the metronomic schedule of the CTX-ACT treatment according to the information acquired by intravital imaging</title><p>Although the CTX-ACT treatment only controlled the tumor growth for several days and displayed no significant difference compared with the CTX treatment group (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), intravital imaging revealed that the CTX-ACT combined treatment elicited a stronger anti-tumor immune response than the CTX treatment alone. To improve the anti-tumor efficacy of the combined immunotherapy, we adopted three rounds of CTX-ACT treatment using a metronomic schedule (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). According to the intravital imaging data, the motility of the adoptive CTLs remained at a high level on Day 5 both at the tumor periphery and in the parenchyma (<xref ref-type="fig" rid="fig3">Figure 3A–D</xref>, <xref ref-type="other" rid="media3">Video 3</xref>). Concomitant with this phenomenon, the anti-tumor response also peaked on Day 5 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig3">Figure 3A,C</xref>), and then the tumor continued to grow (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Before the adoptive CTLs were recruited and activated, the motility of the endogenous TIIs transiently increased on Day 1 and then the TIIs efficiently infiltrated into the tumor parenchyma (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="other" rid="media6">Video 6</xref>). According to these results, an effective interval time of five days between treatment rounds was determined for the CTX-ACT combined therapy. When the anti-tumor effect of the adoptive CTLs decreased, a second round of treatment was implemented to elicit the transient activity of the endogenous TIIs. This approach maintained a specific immune reaction against CFP-B16 tumors in vivo at high levels. When administered three times successfully, the metronomic treatments controlled the growth of the tumor during its entire course, with a significantly more effective tumor growth control compared with the other control groups that received only a single round of the CTX-ACT treatment (p&lt;0.001, <xref ref-type="fig" rid="fig8">Figure 8B</xref>) and the metronomic CTX treatment (p&lt;0.05, <xref ref-type="fig" rid="fig8">Figure 8B</xref>).<fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.056</object-id><label>Figure 8.</label><caption><title>Metronomic CTX-ACT therapy efficiently controlled the growth of CFP-B16 tumors in vivo.</title><p>(<bold>A</bold>) Metronomic therapy schedule of the CTX-ACT treatment. (<bold>B</bold>) Growth curves for CFP-B16 tumors in the different treatment groups. The data are represented as the mean ± SEM tumor volume (n = 12–15, three independent experiments). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001(<xref ref-type="supplementary-material" rid="SD33-data">Figure 8—source data 1</xref>). (<bold>C</bold>) Long-term and large-field intravital images of the tumor microenvironment during CTX-ACT metronomic therapy. Blue, a CFP-B16 tumor; green, EGFP host cells. Scale bar: 500 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.056">http://dx.doi.org/10.7554/eLife.14756.056</ext-link></p><p><supplementary-material id="SD33-data"><object-id pub-id-type="doi">10.7554/eLife.14756.057</object-id><label>Figure 8—source data 1.</label><caption><title>Growth curves for CFP-B16 tumors in the different treatment groups</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.057">http://dx.doi.org/10.7554/eLife.14756.057</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-fig8-data1-v2.pzf"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig8-v2"/></fig></p><p>The entire anti-tumor immune response elicited by the three rounds of metronomic CTX-ACT treatments was captured by long-term intravital imaging. As shown in <xref ref-type="fig" rid="fig8">Figure 8C</xref>, a conflict occurred between the tumor cells and immunocytes. Tumor growth was controlled for four days after the first round of CTX-ACT treatment (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, top row). When the tumor began to regrow one day later, the second treatment was applied, and continued to control the growth of the tumor for an additional four days (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, middle row). The third treatment was applied when the tumor began to regrow, and controlled the growth of the tumor successfully again for several more days (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, bottom row). During this process, the continuous elimination of Tregs, transfusion of adoptive CTLs and activation of endogenous immunocytes (<italic>e.g.</italic>, CTLs, neutrophils and DCs) were required to control the tumor growth.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>To understand the cellular mechanisms underlying tumor immunotherapy, we globally monitored the sequence of events involving multicolor-coded immune cells during CTX-ACT immunotherapy using a tumor-implanted window chamber device (<xref ref-type="bibr" rid="bib52">Schietinger et al., 2013</xref>) and large-field intravital imaging technology. To the best of our knowledge, this study is the first to elucidate the entire process and to provide sequential descriptions of the dynamic spatio-temporal changes in Tregs, adoptive CTLs, endogenous CTLs, endogenous TIIs and DCs in the tumor microenvironment (<xref ref-type="fig" rid="fig9">Figure 9</xref>). In particular, it is worth mentioning that we discovered two symbolic cell events that characterize immunosuppression and immunoactivation: the formation of an immunosuppressive ring of Tregs around the solid tumor, which indicates immune suppression, and the chemotactic movement of endogenous TIIs and infiltration of adoptive CTLs and DCs into the tumor parenchyma, which demonstrate immune activation.<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.058</object-id><label>Figure 9.</label><caption><title>Timeline schematic showing the elicitation of anti-tumor immune responses in the tumor microenvironment by CTX-ACT treatment.</title><p>Step 1: CFP-B16 tumor cells grew and Tregs accumulated in the tumor area before CTX treatment. Step 2: CTX treatment depleted most Tregs, blocking the formation of an ‘immunosuppressive ring’. Step 3: A transient increase in the motility of the endogenous neutrophils is elicited by CTX-ACT treatment on Day 1. Step 4: DCs present increased infiltration on Day 3. Step 5: Adoptive CTLs present increased infiltration and motility and the CTX-ACT treatment retained activated endogenous CTLs in the tumor area on Day 5. Step 6: Solid tumor ‘melting' occurs from the inside and 'shrinking’ occurs from the outside on Days 5–6.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.058">http://dx.doi.org/10.7554/eLife.14756.058</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-14756-fig9-v2"/></fig></p><p>An immunosuppressive environment was caused by the accumulation of a large number of Tregs in the tumor areas. Tregs are considered to play a crucial role in mediating immunosuppression in anti-tumor immune responses (<xref ref-type="bibr" rid="bib66">Zou, 2006</xref>; <xref ref-type="bibr" rid="bib6">Beyer and Schultze, 2006</xref>). By using large-field intravital imaging, we observed that Tregs not only concentrated at the tumor periphery (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) but also formed an immunosuppressive ring around a solid tumor (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>), and adoptive CTLs barely infiltrated solid tumors in the presence of this immunosuppressive ring (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>, <xref ref-type="fig" rid="fig2">Figure 2B</xref>, and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). CTLs must recognize the cognate antigen of tumor cells before they are able to infiltrate into the tumor parenchyma sufficiently (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>; <xref ref-type="bibr" rid="bib35">Mrass et al., 2006</xref>). Thus, we propose that the immunosuppressive ring of Tregs blocked the ability of adoptive CTLs to recognize the cognate antigen of tumor cells and decreased the migration of these CTLs into the tumor area. This conclusion is supported by the increased number of adoptive CTLs infiltrating into the tumor parenchyma after the CTX treatment (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>), which depleted most of the Tregs in the tumor area and blocked the formation of an immunosuppressive ring around the solid tumor (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Additionally, the depletion of the Tregs induced by CTX treatment contributed to the accumulation of adoptive CTLs in the tumor area in three ways: (1) it cleared the immunosuppressive barrier to facilitate the migration of adoptive CTLs into the tumor area; (2) it induced the elevated expression of some chemokines and cytokines in the tumor microenvironment to promote the accumulation of adoptive CTLs (<xref ref-type="bibr" rid="bib11">Bracci et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Schiavoni et al., 2011</xref>); and (3) it provided space to allow the infiltration and homeostatic proliferation of adoptive CTLs (<xref ref-type="bibr" rid="bib11">Bracci et al., 2007</xref>; <xref ref-type="bibr" rid="bib54">Sistigu et al., 2011</xref>).</p><p>As shown in the schematic in <xref ref-type="fig" rid="fig9">Figure 9</xref>, specific endogenous and adoptive anti-tumor immune reactions were triggered by the synergistic effect of the CTX-ACT combined treatment. Endogenous TIIs were activated and underwent chemotactic movements toward the tumor parenchyma within 24 hr (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="other" rid="media6">Video 6</xref>), before endogenous DCs infiltrated into the tumor parenchyma on Day 3 (<xref ref-type="fig" rid="fig7">Figure 7A,C</xref>). In addition, adoptive CTLs accumulated at the tumor periphery, arrested in the tumor parenchyma to contact neighboring tumor cells on Day 3 and then resumed their high-speed migration on Day 5 (<xref ref-type="fig" rid="fig3">Figure 3A,C and F</xref>). On Day 5, the anti-tumor effect elicited synergistically by CTX and ACT in a combined treatment achieved its maximum and promoted external and internal tumor shrinking and melting (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig3">Figure 3A,C</xref>). Our results highlight the importance of metronomic treatments in CTX-ACT therapy, as a designed metronomic CTX-ACT treatment schedule (<xref ref-type="fig" rid="fig8">Figure 8A</xref>) alternately accelerates the endogenous and adoptive anti-tumor immune responses and successfully controls the tumor growth for a long duration (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>).</p><p>The migratory behavior of CTLs in the tumor microenvironment is complicated and changes dynamically. Certain researchers have indicated that T cells need to arrest for a long period at the tumor periphery and that their interaction with tumor cells is crucial for tumor elimination (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>). However, other studies have shown that the random, high speed migration of lymphocytes from the tumor periphery to the tumor center is beneficial for tumor elimination (<xref ref-type="bibr" rid="bib35">Mrass et al., 2006</xref>). In our study, we observed four different stages of adoptive CTL migration in the same tumor region, which occurred during the tumor destruction process over a period of up to seven days after the CTX-ACT combined treatment (<xref ref-type="fig" rid="fig3">Figure 3A, C</xref>, and <xref ref-type="other" rid="media1">Videos 1</xref>–<xref ref-type="other" rid="media4">4</xref>). The adoptive CTLs accumulated at the tumor periphery but barely infiltrated into the tumor parenchyma during the first stage (<xref ref-type="fig" rid="fig3">Figure 3A-D</xref>, <xref ref-type="other" rid="media1">Video 1</xref>). Then, the CTLs formed a long-term interaction with the tumor cells in both the tumor periphery and the tumor parenchyma during the second stage (<xref ref-type="fig" rid="fig3">Figure 3A-D</xref>, <xref ref-type="other" rid="media2">Video 2</xref>). Simultaneously with tumor cell death and elimination, the adoptive CTLs resumed their motility during the third stage (<xref ref-type="fig" rid="fig3">Figure 3A-D</xref>, <xref ref-type="other" rid="media3">Video 3</xref>). Finally, the number and motility of the CTLs rapidly decreased, suggesting CTL dysfunction during the fourth stage (<xref ref-type="fig" rid="fig3">Figure 3A-D</xref>, <xref ref-type="other" rid="media4">Video 4</xref>). Thus, the differences in the behavior of the adoptive CTLs throughout the four stages provide an explanation for the variations observed in the previous reports. Besides the activities of the adoptive CTLs, the dynamic behavior of endogenous CTLs has also been observed in our study. The CTX-ACT combined treatment depleted most of the endogenous T cells in the tumor area, and most of the remaining endogenous T cells were activated CD8<sup>+</sup> CTLs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–C</xref>). While the adoptive CTLs had complex migratory behaviors during the four different stages, the endogenous CTLs arrested at the tumor area for a long time and showed confined movement so that they formed stable interactions with tumor cells and then effectively destroyed them (<xref ref-type="fig" rid="fig4">Figure 4A,C–F</xref>).</p><p>In recent years, the interest in tumor-associated neutrophils (TANs) has increased, and accumulating data have demonstrated that TANs play dichotomous roles because they exhibit both pro-tumor and anti-tumor effects during tumor progression (<xref ref-type="bibr" rid="bib32">Mantovani et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Piccard et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Brandau et al., 2013</xref>). Previous studies have demonstrated that during the early stage of tumor progression, accumulating TANs with high motility ((<xref ref-type="bibr" rid="bib62">Yao et al., 2015</xref>), also described as TENs (<xref ref-type="bibr" rid="bib24">Granot et al., 2011</xref>)), play an important role in the anti-tumor response by exerting a direct cytotoxic effect on tumor cells (<xref ref-type="bibr" rid="bib25">Hicks et al., 2006</xref>), enhancing antibody-induced anti-tumor effects (<xref ref-type="bibr" rid="bib1">Albanesi et al., 2013</xref>), and having a stimulatory effect on T cell proliferation (<xref ref-type="bibr" rid="bib22">Eruslanov et al., 2014</xref>). In the present study, more than 50% of the TIIs were neutrophils at a very early stage (Day 1) after the CTX-ACT treatment (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) and exhibited a high motility. Thus, we assumed that these neutrophils were TENs with anti-tumor effects. After the CTX-ACT combined treatment, the endogenous TENs transiently moved (within 24 hr) with high speed via chemotaxis toward the tumor parenchyma (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig6">6</xref>), and their motility increased before the accumulation of adoptive CTLs and DCs (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig7">7A</xref>). Intravital imaging showed that the number of DCs increased significantly on Day 3 after the CTX-ACT treatment (<xref ref-type="fig" rid="fig7">Figure 7A,B</xref>). Some DCs displayed mature phenotypes in the tumor tissues of CTX-ACT-treated mice and presented high MHC-II and CD86 expression (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). A large number of DCs infiltrating into the tumor parenchyma has been shown to have a positive association with longer survival of cancer patients (<xref ref-type="bibr" rid="bib15">Chaput et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Pagès et al., 2010</xref>). Notably, the recruitment of DCs into the tumor area occurred earlier than the solid tumor ‘melting’ from the inside. This phenomenon suggests that the infiltrated DCs may take up tumor antigens and present them to T cells (<xref ref-type="bibr" rid="bib47">Restifo et al., 2012</xref>) to further elicit the anti-tumor immune response.</p><p>Most previous studies applied the OT-I system with K<sup>b</sup>-OVA as a model antigen in T lymphoma cells to observe the migratory behavior of antigen-specific CTLs in solid tumors (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Breart et al., 2008</xref>; <xref ref-type="bibr" rid="bib8">Boissonnas et al., 2013</xref>). However, cancer cell antigens are expressed at a low level in most patients (<xref ref-type="bibr" rid="bib47">Restifo et al., 2012</xref>). Thus, the K<sup>b</sup>-OVA antigen tumor model could not completely mimic the clinical presentation. In the present study, by contrast, we designed an experimental system to mimic ACT immunotherapy using whole tumor cell antigens to prime and activate the CTLs.</p><p>In summary, the CTX-ACT combined treatment displayed synergistic anti-tumor effects by blocking the formation of an immunosuppressive ring around solid tumors by Tregs, eliciting the transient migratory activity of TIIs toward the tumor parenchyma, and accelerating the infiltration of adoptive CTLs and endogenous DCs into the tumor. The CTX-ACT treatment not only promoted the anti-tumor effects of adoptive CTLs but also elicited endogenous anti-tumor immune responses. Guided by the results obtained by intravital imaging, three rounds of metronomic CTX-ACT treatments successfully controlled the tumor growth for several weeks. Thus, our long-term intravital imaging of the multicolor-coded tumor microenvironment provides new perspectives regarding the cellular mechanisms underlying the success or failure of cancer immunotherapies,and will facilitate improvements in the efficacy of combination immunotherapy. Furthermore, the method of long-term intravital imaging of various immune cells in the tumor microenvironment in vivo is also suitable for monitoring multiple immune reactions, studying the spatio-temporal cellular events of other immunotherapies, such as checkpoint inhibitors (CTLA-4 antibody and PD-1/PD-L1 antibodies), and comparing the efficacy of classical immunotherapies (such as the CTX-ACT combined treatment) and checkpoint inhibitors in the treatment of different tumor models.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>C57BL/6 female mice and BALB/c nude mice (of 6–12 weeks old) were obtained from Hunan Slack King of Laboratory Animal Co., Ltd (Hunan, China). B6.Cg-<italic>Tg (Itgax-Venus) 1Mnz</italic>/J (<italic>CD11c</italic>-YFP, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:008829">IMSR_JAX:008829</ext-link>) mice, C57BL/6-<italic>Foxp3<sup>tm1Flv</sup></italic>/J (<italic>Foxp3</italic>-mRFP, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:008374">IMSR_JAX:008374</ext-link>) mice and B6.129P2-<italic>Cxcr6<sup>tm1Litt</sup></italic>/J (<italic>Cxcr6<sup>+/gfp</sup></italic>, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:005693">IMSR_JAX:005693</ext-link>) mice were derived from breeding pairs that were originally obtained from Jackson Laboratory (Bar Harbor, ME). To generate multicolor-coded transgenic mice, <italic>CD11c</italic>-YFP mice were hybridized with <italic>Foxp3</italic>-mRFP mice. C57BL/6-<italic>Tg (CAG-EGFP)</italic>/J mice, that express EGFP throughout the entire body, excluding erythrocytes and hair, were generously provided by Dr. Zhiying He (Second Military Medical University, Shanghai, China). All of the mice were bred and maintained in a specific pathogen-free (SPF) barrier facility at Animal Center of Wuhan National Laboratory for Optoelectronics. All animal studies were approved by the Hubei Provincial Animal Care and Use Committee and followed the experimental guidelines of the Animal Experimentation Ethics Committee of Huazhong University of Science and Technology.</p></sec><sec id="s4-2"><title>Tumor cells</title><p>B16 melanoma cells were purchased from Boshide Biology Ltd. China (RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_F936">CVCL_F936</ext-link>). The B16 cell line was stably transfected with the PB transposon system (<xref ref-type="bibr" rid="bib20">Ding et al., 2005</xref>) (a gift from Dr. Xiaohui Wu, Fudan University, Shanghai, China), which contained the sequence encoding mCerulean to generate the CFP-B16 tumor cell line. All cell lines were mycoplasma-negative as determined by screening using the MycoProbe Mycoplasma Detection Kit (R and D Systems, Minneapolis, MN). The CFP-B16 cell line was authenticated using the Cell Line Authentication Service by short-tandem repeat (STR) profiling carried out by Beijing Microread Genetics Co., Ltd. (Beijing, China). These cells were cultured in RPMI-1640 medium (HyClone, Beijing, China) containing 1% penicillin-streptomycin (HyClone) and 10% fetal bovine serum (FBS, HyClone).</p></sec><sec id="s4-3"><title>Production of CFP-B16 reactive T cells</title><p>T cells that were reactive with CFP-B16 were established from C57BL/6 mice using an immunization strategy consisting of a series of tumor cellchallenges. First, the C57BL/6 mice were immunized subcutaneously in both flanks with 2.5 × 10<sup>6</sup> CFP-B16 cells (pretreated with 50 μg ml<sup>−1</sup> mitomycin C [Sigma-Aldrich, Saint Louis, MO] for 2 hr at 37°C). Seven days after the primary immunization, the mice were immunized using the same methods. Seven days after the rechallenge, the mice were euthanized, and their spleens were dissected to prepare immunocytes. Spleen-derived cells (1–2 × 10<sup>6</sup> per ml) were cultured in 24-well plates (Costar, Suzhou, China) with RPMI-1640 medium (HyClone), 10% FBS (HyClone), IL-2 (50 U ml<sup>−1</sup>, Peprotech, Rocky Hill, NJ, USA) and CFP-B16 whole-cell antigen (50 μg ml<sup>-1</sup>, supernatant from freeze-thawed tumor cell lysate). Three days later, when the CTLs became confluent, the cells were split 1:2 to 1:4 into new 24-well plates using fresh complete medium with whole-cell antigen and IL-2. The method of generating CFP-B16 CTLs in vitro is discussed in the book ‘Current protocols in Immunology’ (<xref ref-type="bibr" rid="bib48">Restifo and Nicholas, 2011</xref>) and in previous reports (<xref ref-type="bibr" rid="bib29">Liu et al., 2006</xref>; <xref ref-type="bibr" rid="bib4">Bauer et al., 2014</xref>).</p></sec><sec id="s4-4"><title>Cytotoxicity assays and flow cytometry</title><p>The cytotoxicity of the CTLs was evaluated using CFSE and PI dual-staining assays. Target cells (CFP-B16 and normal C57BL/6 splenocytes) were labeled with 5 μM CFSE (Invitrogen, Eugene, OR) for 15 min at 37°C. The CTLs were collected from cultured lymphocytes by centrifugation in Histopaque−1.083 (Sigma-Aldrich, Saint Louis, MO) and co-cultivated with CFSE-labeled target cells in 96-well U-bottom plates (Costar, Suzhou, China) at different E:T ratios (25:1, 12.5:1, 5:1, 2.5:1, 1.25:1, 0.5:1, and 0.25:1). After the cells were incubated for 4 hr at 37°C, the mixed cells were labeled with 5 μM PI (Sigma-Aldrich, Saint Louis, MO) in the dark for 10 min. The dual fluorescent signals of the target cells were analyzed using a FACS-Calibur flow cytometer (Guava EasyCyte 8HT, EMD Millipore Corporation, Darmstadt, Germany).</p><p>The percentage of CTL-specific lysis was calculated according to the following formula:</p><p>Cytotoxicity (%) = [(experimental dead target cells (%) − spontaneous dead target cells (%)) / (1 − spontaneous dead target cells (%))]×100.</p><p>Before the adoptive transfer, the activity and quality of a number of CTLs cultured in vitro were tested. The CTLs were incubated with anti-mouse CD 16/32 (Fc block, Cat# 101302, Biolegend, San Diego, CA; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312801">AB_312801</ext-link>) for 10 min, and then they were stained with various antibodies at 4°C in the dark for 30 min and washed once with PBS (HyClone). The supernatants were discarded, and the cell pellets were resuspended in 0.2 ml PBS before analysis using a FACS-Calibur flow cytometer (Guava EasyCyte 8HT). Typically, 10,000 events were assessed. For the intracellular cytokine staining, the CTLs were stimulated with whole CFP-B16 cell antigen in the presence of Brefeldin A (10 μg ml<sup>−1</sup>, eBioscience, San Diego, CA), and the cells were maintained in Brefeldin A until fixation and then prepared as previously described. CD3-PE (Cat# 100308, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312673">AB_312673</ext-link>), CD3-APC/Cy7 (Cat# 100329, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1877171">AB_1877171</ext-link>), CD8-FITC (Cat# 100705, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312744">AB_312744</ext-link>), CD8-PE/Cy7 (Cat# 100722, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312761">AB_312761</ext-link>), CD4-APC (Cat# 100412, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312697">AB_312697</ext-link>), CD25-FITC (Cat# 102005, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312854">AB_312854</ext-link>), CD69-PerCP/Cy5.5 (Cat# 104521, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_940497">AB_940497</ext-link>), CD11b-APC (Cat# 101211, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312794">AB_312794</ext-link>), Ly6c-PerCP/Cy5.5 (Cat# 128012, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1659241">AB_1659241</ext-link>), Ly6G-APC/Cy7 (Cat# 127624, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10640819">AB_10640819</ext-link>), Gr1-PerCP/Cy5.5 (Cat# 108427, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_893561">AB_893561</ext-link>), CD45-PE (Cat# 103106, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312971">AB_312971</ext-link>) and IFNγ-APC (Cat# 505809, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_315403">AB_315403</ext-link>) (all obtained from Biolegend, San Diego, CA), and Granzyme B-PerCP-eFluor 710 (Cat# 46-8898–80, eBioscience, San Diego, CA; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11217678">AB_11217678</ext-link>) were used.</p></sec><sec id="s4-5"><title>In vivo tumor growth and combination immunotherapy</title><p>CFP-B16 melanoma cells (5 × 10<sup>5</sup>) were subcutaneously implanted in the right flank of C57BL/6 mice (females, 6–8 weeks old). The tumor size was measured at five days post-implantation using a digital caliper. The volume of the tumor was calculated as V = L (length) × W (width) × H (height)/2 (<xref ref-type="bibr" rid="bib26">Huang et al., 2013</xref>). Four days after the tumor inoculation, the mice in the CTX (Sigma-Aldrich, Saint Louis, MO) treatment group received an intraperitoneal (i.p.) injection of CTX diluted in sterile distilled H<sub>2</sub>O at a concentration of 50 mg kg<sup>−1</sup>, 100 mg kg<sup>−1</sup> and 150 mg kg<sup>−1</sup>. Six days after tumor inoculation, the mice of the ACT and CTX-ACT groups were intravenously (i.v.) injected with 5 × 10<sup>6</sup> adoptive CTLs (250 μL total volume). The CTLs (five days after in vitro stimulation) were collected and prepared by centrifugation in Histopaque−1.083 (Sigma-Aldrich, Saint Louis, MO), washed three times and resuspended in ice-cold HBSS (HyClone). For the metronomic CTX-ACT treatment, the CTX dose schedule was 150 mg kg<sup>−1</sup> CTX injected i.p. on days 4, 9 and 14 after CFP-B16 tumor cell implantation followed by 5 × 10<sup>6</sup> CTLs (250 μL total volume) injected i.v. two days after CTX injection.</p></sec><sec id="s4-6"><title>Histologic analysis and immunofluorescence staining</title><p>Tumor tissues were fixed in 4% paraformaldehyde for 24–48 hr at 4°C, they were embedded in paraffin, sectioned, and stained with HE. For the immunohistochemical analysis, the sections were stained with markers of regulatory T cells (anti-Foxp3 antibody, 1:800, ab54501, Abcam, Cambridge, United Kingdom; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_880110">AB_880110</ext-link>).</p><p>For the immunofluorescence analysis, tumor tissues were fixed in 4% paraformaldehyde for 24–48 hr at 4°C and then subjected to sequential dehydration in 10%, 20%, and 30% sucrose solution. The tissues were then frozen in OCT (Sakura, Torrance, CA) compound and cut into 20 μm slices. OCT was removed by three washes in PBS, and the tumor tissues containing EGFP cells were immunostained with Alexa Fluor 594 anti-mouse CD3 (1:150, Cat# 100240, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2563427">AB_2563427</ext-link>), Alexa Fluor 647 anti-mouse CD4 (1:100, Cat# 100424, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_389324">AB_389324</ext-link>), Alexa Fluor 647 anti-mouse CD8 (1:100, Cat# 100724, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_389326">AB_389326</ext-link>), Alexa Fluor 700 anti-mouse Ly6G (1:200, Cat# 127622, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10643269">AB_10643269</ext-link>), and Alexa Fluor 647 anti-mouse F4/80 (1:200, Cat# 123122, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_893480">AB_893480</ext-link>) antibodies (all of which were obtained from Biolegend, San Diego, CA) to identify the T cells, neutrophils and macrophages, respectively. The tumor tissues containing YFP-DCs were immunostained with anti-MHC II (1:200, ab15630, Abcam, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_302007">AB_302007</ext-link>) and anti-CD86 (1:100, ab25376, Abcam, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_470491">AB_470491</ext-link>) and then incubated with mouse monoclonal anti-rat IgG2b/IgG 2a conjugated to Alexa Fluor 647 (1:2000, ab172333 and ab172335, Abcam, Cambridge, United Kingdom). CLSM was performed using a LSM710 (Carl Zeiss MicroImaging, Inc., Jena, Germany) with a 20× objective (N.A. 0.8).</p></sec><sec id="s4-7"><title>Preparation of the skin-fold window chamber and injection of CFP-B16 tumor cells</title><p>The window chambers were prepared as previously described (<xref ref-type="bibr" rid="bib41">Palmer et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Schietinger et al., 2013</xref>). Hair was removed from the back of the mouse one day before surgery. For the window chamber surgery, the mice were anesthetized by i.p. injecting a mix of ketamine (100 mg kg<sup>−1</sup>, Sigma-Aldrich, Saint Louis, MO) and xylazine (10 mg kg<sup>−1</sup>, Sigma-Aldrich, Saint Louis, MO) and positioned on a warmer plate at 37°C (Thermo Plate, TOKAI HIT, Shizuoka-ken, Japan). The skin on the back of the mice was sterilized with 70% alcohol and iodine solution. Titanium window frames (APJ Trading Co., Inc., Ventura, CA) were implanted onto the back of the mouse, and then, a hole with a diameter of 1 cm was dissected by removing the skin and fascia on one side of the dorsal skin-fold flap while maintaining the integrity of the opposing dermis, fascial plane and vasculature. One day later, CFP-B16 tumor cells (5 × 10<sup>5</sup> resuspended in 25 μL PBS) were injected at one site near the major vessel and between the fascia and dermis of the rear skin. The entire surgical process was conducted under sterile conditions to avoid infection. To relieve pain associated with surgery and inflammation, the mice received Tolfedine via i.p. injection (16.25 mg kg<sup>−1</sup>, Vétoquinol, Québec, Canada) immediately and within 24 hr after implantation.</p></sec><sec id="s4-8"><title>Preparation of fluorescent dye labeled adoptive CTLs for intravital imaging</title><p>For intravital imaging, the adoptive CTLs were labeled with 25 μM CFSE (Invitrogen, Eugene, OR or 25 μM CellTracker Red CMTPX Dye (Invitrogen, Eugene, OR) for 15–45 min at 37°C as the standardized protocols described.</p></sec><sec id="s4-9"><title>Intravital imaging of the tumor microenvironment</title><p>The window-chamber mice were anesthetized by inhalation of 1.0–3.0% isoflurane in oxygen flow using a Matrx VMS small animal anesthesia machine (Midmark, Dayton, OH). The window was fixed on a warm plate (Thermo Plate) using a custom-made holder and then fastened to the microscope stage. Intravital images (<xref ref-type="bibr" rid="bib45">Qu et al., 2012</xref>) were obtained using an A1R MP+ System (Nikon, Tokyo, Japan) with the large-field imaging function on a motorized stage. The images were captured using a 16× water immersion objective (N.A. 0.8) or 20× objective (N.A. 0.75, Nikon, Japan). Throughout the intravital imaging process, the temperature of the mice was maintained at 37°C with a warm plate. Using large-field imaging technology combined with blood vessel imaging as a ‘position mark’, the same imaging region could be focused on and images of the tumor could be obtained on different days. Confocal laser scanning microscopy (CLSM) was used to simultaneously image the CFP-B16 cells (405 nm laser, 400–500 nm emission), mRFP-Tregs and CMTPX-labeled adoptive CTLs (561 nm laser, 570–620 nm emission), CFSE-labeled adoptive CTLs and <italic>Cxcr6</italic>-GFP cells (488 nm laser, 500–550 nm emission). For the simultaneous imaging of the CFP-B16 cells and EGFP cells in vivo, multi-photon excitation microscopy was applied with an excitation wavelength of 860 nm.</p></sec><sec id="s4-10"><title>Data analysis</title><p>Intravital cell movement was tracked and analyzed with Image-Pro Plus (Media Cybernetics, Inc., Rockville, MD; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_007369">SCR_007369</ext-link>) or Imaris 7.6 (Bitplane AG, Zurich, Switzerland; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_007370">SCR_007370</ext-link>) software. The mean velocity, arrest coefficient, confinement ratio and mean displacement were calculated using Post-TrackObject software (custom-designed software) as previously described (<xref ref-type="bibr" rid="bib56">Sumen et al., 2004</xref>; <xref ref-type="bibr" rid="bib27">Hugues et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Cahalan and Parker, 2008</xref>; <xref ref-type="bibr" rid="bib33">Matheu et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Miller et al., 2002</xref>). The arrest coefficient was calculated as the percentage of time that the instantaneous velocity of each cell was less than 2 μm min<sup>−1 </sup>(<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>), and the confinement ratio was calculated as the ratio of the maximum displacement of a given cell to its path length within a given time (<xref ref-type="bibr" rid="bib14">Cahalan and Parker, 2008</xref>). Cells with a mean velocity of less than 2 μm min<sup>−1</sup> were defined as immotile (<xref ref-type="bibr" rid="bib7">Boissonnas et al., 2007</xref>). The mean displacement plotted against the square root of time was calculated as previously described (<xref ref-type="bibr" rid="bib50">Ruocco et al., 2012</xref>). Linear fitting was then performed on the plotted curves to determine whether the cells underwent random walking (<xref ref-type="bibr" rid="bib14">Cahalan and Parker, 2008</xref>). An R<sup>2</sup>&gt;0.95 was evaluated as a good fit and the corresponding cell population was considered to be executing random walking.</p></sec><sec id="s4-11"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>). For comparisons of three or more groups, the Kruskal-Wallis test was performed and followed by Dunn’s multiple comparison tests (<xref ref-type="bibr" rid="bib35">Mrass et al., 2006</xref>). For comparisons of two groups, the two-tailed unpaired <italic>t</italic>-test was performed. The statistical analysis is described in each figure legend.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Honglin Jin (Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China), Dr. Wei Chen (University of Central Oklahoma) for paper discussion and Dr. Xiaohui Wu of Fudan University (China) for providing PB transposon system. We also thank Dr. Xiangning Li, Xiaohua Lv and Xiuli Liu of the Optical Bioimaging Core Facility of WNLO-HUST for the support in data acquisition. This work was supported by the Major Research plan of the National Natural Science Foundation of China (Grant No. 91442201), the National Basic Research Program of China (Grant No. 2011CB910401), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (Grant No. 61421064), the Fundamental Research Funds for the Central Universities (HUST: 2015ZDTD014), the Director Fund of WNLO, and the 111 Project (No. B07038).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>SQ, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con2"><p>HL, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>LLu, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>ZQ, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>LLi, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>LC, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>GS, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con8"><p>LF, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con9"><p>QL, Conception and design, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con10"><p>ZZ, Conception and design, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of Hubei Provincial Animal Care and Use Committee. The protocol was approved by the Animal Experimentation Ethics Committee of Huazhong University of Science and Technology (reference number: 452). All surgery was performed under ketamine and xylazine, and all intravital imaging experiments were performed under 1-3% isoflurane in oxygen, every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD34-data"><object-id pub-id-type="doi">10.7554/eLife.14756.059</object-id><label>Source code 1.</label><caption><title>The CellTracking_GUI.m is the main program of the Post-TrackObject software.</title><p>The Post-TrackObject software is designed based on the Matlab (R2012, MathWorks) GUI.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.059">http://dx.doi.org/10.7554/eLife.14756.059</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-code1-v2.fig"/></supplementary-material><supplementary-material id="SD35-data"><object-id pub-id-type="doi">10.7554/eLife.14756.060</object-id><label>Source code 2.</label><caption><title>The CellTracking_GUI.fig is the main user interface of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.060">http://dx.doi.org/10.7554/eLife.14756.060</ext-link></p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-14756-code2-v2.fig"/></supplementary-material><supplementary-material id="SD36-data"><object-id pub-id-type="doi">10.7554/eLife.14756.061</object-id><label>Source code 3.</label><caption><title>The CellTracking_GUI_Trajectory.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.061">http://dx.doi.org/10.7554/eLife.14756.061</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code3-v2.m"/></supplementary-material><supplementary-material id="SD37-data"><object-id pub-id-type="doi">10.7554/eLife.14756.062</object-id><label>Source code 4.</label><caption><title>The conrat.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.062">http://dx.doi.org/10.7554/eLife.14756.062</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code4-v2.m"/></supplementary-material><supplementary-material id="SD38-data"><object-id pub-id-type="doi">10.7554/eLife.14756.063</object-id><label>Source code 5.</label><caption><title>The dmean_motcoe.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.063">http://dx.doi.org/10.7554/eLife.14756.063</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code5-v2.m"/></supplementary-material><supplementary-material id="SD39-data"><object-id pub-id-type="doi">10.7554/eLife.14756.064</object-id><label>Source code 6.</label><caption><title>The mdmot_eb.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.064">http://dx.doi.org/10.7554/eLife.14756.064</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code6-v2.m"/></supplementary-material><supplementary-material id="SD40-data"><object-id pub-id-type="doi">10.7554/eLife.14756.065</object-id><label>Source code 7.</label><caption><title>The mean_sem.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.065">http://dx.doi.org/10.7554/eLife.14756.065</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code7-v2.m"/></supplementary-material><supplementary-material id="SD41-data"><object-id pub-id-type="doi">10.7554/eLife.14756.066</object-id><label>Source code 8.</label><caption><title>The trajectory.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.066">http://dx.doi.org/10.7554/eLife.14756.066</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code8-v2.m"/></supplementary-material><supplementary-material id="SD42-data"><object-id pub-id-type="doi">10.7554/eLife.14756.067</object-id><label>Source code 9.</label><caption><title>The vmean_arrcoe.m is the subprogram of the Post-TrackObject software</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.067">http://dx.doi.org/10.7554/eLife.14756.067</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code9-v2.m"/></supplementary-material><supplementary-material id="SD43-data"><object-id pub-id-type="doi">10.7554/eLife.14756.068</object-id><label>Source code 10.</label><caption><title>The CellTracking_GUI_Trajectory.fig is the subinterface which corresponds to the subprogram CellTracking_GUI_Trajectory.m.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.068">http://dx.doi.org/10.7554/eLife.14756.068</ext-link></p></caption><media mime-subtype="x-m" mimetype="text" xlink:href="elife-14756-code10-v2.m"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albanesi</surname><given-names>M</given-names></name><name><surname>Mancardi</surname><given-names>DA</given-names></name><name><surname>Jönsson</surname><given-names>F</given-names></name><name><surname>Iannascoli</surname><given-names>B</given-names></name><name><surname>Fiette</surname><given-names>L</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name><name><surname>Bruhns</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neutrophils mediate antibody-induced antitumor effects in mice</article-title><source>Blood</source><volume>122</volume><fpage>3160</fpage><lpage>3164</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-04-497446</pub-id><pub-id pub-id-type="pmid">23980063</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antony</surname><given-names>PA</given-names></name><name><surname>Piccirillo</surname><given-names>CA</given-names></name><name><surname>Akpinarli</surname><given-names>A</given-names></name><name><surname>Finkelstein</surname><given-names>SE</given-names></name><name><surname>Speiss</surname><given-names>PJ</given-names></name><name><surname>Surman</surname><given-names>DR</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Overwijk</surname><given-names>WW</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells</article-title><source>Journal of Immunology</source><volume>174</volume><fpage>2591</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.5.2591</pub-id><pub-id pub-id-type="pmid">15728465</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baitsch</surname><given-names>L</given-names></name><name><surname>Baumgaertner</surname><given-names>P</given-names></name><name><surname>Devêvre</surname><given-names>E</given-names></name><name><surname>Raghav</surname><given-names>SK</given-names></name><name><surname>Legat</surname><given-names>A</given-names></name><name><surname>Barba</surname><given-names>L</given-names></name><name><surname>Wieckowski</surname><given-names>S</given-names></name><name><surname>Bouzourene</surname><given-names>H</given-names></name><name><surname>Deplancke</surname><given-names>B</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Rufer</surname><given-names>N</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>2350</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1172/JCI46102</pub-id><pub-id pub-id-type="pmid">21555851</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>CA</given-names></name><name><surname>Kim</surname><given-names>EY</given-names></name><name><surname>Marangoni</surname><given-names>F</given-names></name><name><surname>Carrizosa</surname><given-names>E</given-names></name><name><surname>Claudio</surname><given-names>NM</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>2425</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1172/JCI66375</pub-id><pub-id pub-id-type="pmid">24812664</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benlalam</surname><given-names>H</given-names></name><name><surname>Vignard</surname><given-names>V</given-names></name><name><surname>Khammari</surname><given-names>A</given-names></name><name><surname>Bonnin</surname><given-names>A</given-names></name><name><surname>Godet</surname><given-names>Y</given-names></name><name><surname>Pandolfino</surname><given-names>M-C</given-names></name><name><surname>Jotereau</surname><given-names>F</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Labarrière</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients</article-title><source>Cancer Immunology, Immunotherapy</source><volume>56</volume><fpage>515</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1007/s00262-006-0204-0</pub-id><pub-id pub-id-type="pmid">16874485</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulatory T cells in cancer</article-title><source>Blood</source><volume>108</volume><fpage>804</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-02-002774</pub-id><pub-id pub-id-type="pmid">16861339</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boissonnas</surname><given-names>A</given-names></name><name><surname>Fetler</surname><given-names>L</given-names></name><name><surname>Zeelenberg</surname><given-names>IS</given-names></name><name><surname>Hugues</surname><given-names>S</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor</article-title><source>Journal of Experimental Medicine</source><volume>204</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1084/jem.20061890</pub-id><pub-id pub-id-type="pmid">17261634</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boissonnas</surname><given-names>A</given-names></name><name><surname>Licata</surname><given-names>F</given-names></name><name><surname>Poupel</surname><given-names>L</given-names></name><name><surname>Jacquelin</surname><given-names>S</given-names></name><name><surname>Fetler</surname><given-names>L</given-names></name><name><surname>Krumeich</surname><given-names>S</given-names></name><name><surname>Théry</surname><given-names>C</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Combadière</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network</article-title><source>Neoplasia</source><volume>15</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1593/neo.121572</pub-id><pub-id pub-id-type="pmid">23359264</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Van den Eynde</surname><given-names>B</given-names></name><name><surname>van der Bruggen</surname><given-names>P</given-names></name><name><surname>Van Pel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tumor antigens recognized by T lymphocytes</article-title><source>Annual Review of Immunology</source><volume>12</volume><fpage>337</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.12.040194.002005</pub-id><pub-id pub-id-type="pmid">8011285</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourzac</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Medical imaging: Removing the blindfold</article-title><source>Nature</source><volume>504</volume><fpage>S10</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/504S10a</pub-id><pub-id pub-id-type="pmid">24352358</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracci</surname><given-names>L</given-names></name><name><surname>Moschella</surname><given-names>F</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>La Sorsa</surname><given-names>V</given-names></name><name><surname>Valentini</surname><given-names>M</given-names></name><name><surname>Canini</surname><given-names>I</given-names></name><name><surname>Baccarini</surname><given-names>S</given-names></name><name><surname>Maccari</surname><given-names>S</given-names></name><name><surname>Ramoni</surname><given-names>C</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><name><surname>Proietti</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration</article-title><source>Clinical Cancer Research</source><volume>13</volume><fpage>644</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1209</pub-id><pub-id pub-id-type="pmid">17255288</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandau</surname><given-names>S</given-names></name><name><surname>Dumitru</surname><given-names>CA</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protumor and antitumor functions of neutrophil granulocytes</article-title><source>Seminars in Immunopathology</source><volume>35</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1007/s00281-012-0344-6</pub-id><pub-id pub-id-type="pmid">23007469</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breart</surname><given-names>B</given-names></name><name><surname>Lemaître</surname><given-names>F</given-names></name><name><surname>Celli</surname><given-names>S</given-names></name><name><surname>Bousso</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice</article-title><source>Journal of Clinical Investigation</source><volume>118</volume><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1172/JCI34388</pub-id><pub-id pub-id-type="pmid">18357341</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Choreography of cell motility and interaction dynamics imaged by two-photon microscopy in lymphoid organs</article-title><source>Annual Review of Immunology</source><volume>26</volume><fpage>585</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.24.021605.090620</pub-id><pub-id pub-id-type="pmid">18173372</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Conforti</surname><given-names>R</given-names></name><name><surname>Viaud</surname><given-names>S</given-names></name><name><surname>Spatz</surname><given-names>A</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The Janus face of dendritic cells in cancer</article-title><source>Oncogene</source><volume>27</volume><fpage>5920</fpage><lpage>5931</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.270</pub-id><pub-id pub-id-type="pmid">18836473</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ML</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Gorelik</surname><given-names>L</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name><name><surname>Khazaie</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo</article-title><source>PNAS</source><volume>102</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1073/pnas.0408197102</pub-id><pub-id pub-id-type="pmid">15623559</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couzin-Frankel</surname><given-names>J</given-names></name><name><surname>McNutt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Breakthrough of the year 2013. Cancer immunotherapy</article-title><source>Science</source><volume>342</volume><fpage>1432</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1126/science.342.6165.1432</pub-id><pub-id pub-id-type="pmid">24357284</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couzin-Frankel</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Breakthrough of the year 2013. Cancer immunotherapy</article-title><source>Science</source><volume>342</volume><fpage>1432</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1126/science.342.6165.1432</pub-id><pub-id pub-id-type="pmid">24357284</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Evdemon-Hogan</surname><given-names>M</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title><source>Nature Medicine</source><volume>10</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1038/nm1093</pub-id><pub-id pub-id-type="pmid">15322536</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice</article-title><source>Cell</source><volume>122</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.07.013</pub-id><pub-id pub-id-type="pmid">16096065</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elert</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calling cells to arms</article-title><source>Nature</source><volume>504</volume><fpage>S2</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/504S2a</pub-id><pub-id pub-id-type="pmid">24352361</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eruslanov</surname><given-names>EB</given-names></name><name><surname>Bhojnagarwala</surname><given-names>PS</given-names></name><name><surname>Quatromoni</surname><given-names>JG</given-names></name><name><surname>Stephen</surname><given-names>TL</given-names></name><name><surname>Ranganathan</surname><given-names>A</given-names></name><name><surname>Deshpande</surname><given-names>C</given-names></name><name><surname>Akimova</surname><given-names>T</given-names></name><name><surname>Vachani</surname><given-names>A</given-names></name><name><surname>Litzky</surname><given-names>L</given-names></name><name><surname>Hancock</surname><given-names>WW</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>5466</fpage><lpage>5480</lpage><pub-id pub-id-type="doi">10.1172/JCI77053</pub-id><pub-id pub-id-type="pmid">25384214</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Schreiber</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Innate and adaptive immune cells in the tumor microenvironment</article-title><source>Nature Immunology</source><volume>14</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1038/ni.2703</pub-id><pub-id pub-id-type="pmid">24048123</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granot</surname><given-names>Z</given-names></name><name><surname>Henke</surname><given-names>E</given-names></name><name><surname>Comen</surname><given-names>EA</given-names></name><name><surname>King</surname><given-names>TA</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Benezra</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tumor entrained neutrophils inhibit seeding in the premetastatic lung</article-title><source>Cancer Cell</source><volume>20</volume><fpage>300</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.08.012</pub-id><pub-id pub-id-type="pmid">21907922</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>AM</given-names></name><name><surname>Riedlinger</surname><given-names>G</given-names></name><name><surname>Willingham</surname><given-names>MC</given-names></name><name><surname>Alexander-Miller</surname><given-names>MA</given-names></name><name><surname>Von Kap-Herr</surname><given-names>C</given-names></name><name><surname>Pettenati</surname><given-names>MJ</given-names></name><name><surname>Sanders</surname><given-names>AM</given-names></name><name><surname>Weir</surname><given-names>HM</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>AJG</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Transferable anticancer innate immunity in spontaneous regression/complete resistance mice</article-title><source>PNAS</source><volume>103</volume><fpage>7753</fpage><lpage>7758</lpage><pub-id pub-id-type="doi">10.1073/pnas.0602382103</pub-id><pub-id pub-id-type="pmid">16682640</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo</article-title><source>ACS Nano</source><volume>7</volume><fpage>5791</fpage><lpage>5800</lpage><pub-id pub-id-type="doi">10.1021/nn400683s</pub-id><pub-id pub-id-type="pmid">23790040</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugues</surname><given-names>S</given-names></name><name><surname>Scholer</surname><given-names>A</given-names></name><name><surname>Boissonnas</surname><given-names>A</given-names></name><name><surname>Nussbaum</surname><given-names>A</given-names></name><name><surname>Combadière</surname><given-names>C</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Fetler</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses</article-title><source>Nature Immunology</source><volume>8</volume><fpage>921</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1038/ni1495</pub-id><pub-id pub-id-type="pmid">17660821</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krummel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Illuminating emergent activity in the immune system by real-time imaging</article-title><source>Nature Immunology</source><volume>11</volume><fpage>554</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/ni0710-554</pub-id><pub-id pub-id-type="pmid">20562836</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Caldwell</surname><given-names>SA</given-names></name><name><surname>Greeneltch</surname><given-names>KM</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Abrams</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape</article-title><source>Journal of Immunology</source><volume>176</volume><fpage>3374</fpage><lpage>3382</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.6.3374</pub-id><pub-id pub-id-type="pmid">16517705</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses</article-title><source>Cancer Research</source><volume>65</volume><fpage>4955</fpage><lpage>4962</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3957</pub-id><pub-id pub-id-type="pmid">15930318</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackensen</surname><given-names>A</given-names></name><name><surname>Meidenbauer</surname><given-names>N</given-names></name><name><surname>Vogl</surname><given-names>S</given-names></name><name><surname>Laumer</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Andreesen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma</article-title><source>Journal of Clinical Oncology</source><volume>24</volume><fpage>5060</fpage><lpage>5069</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.1100</pub-id><pub-id pub-id-type="pmid">17075125</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Cassatella</surname><given-names>MA</given-names></name><name><surname>Costantini</surname><given-names>C</given-names></name><name><surname>Jaillon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Neutrophils in the activation and regulation of innate and adaptive immunity</article-title><source>Nature Reviews Immunology</source><volume>11</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1038/nri3024</pub-id><pub-id pub-id-type="pmid">21785456</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matheu</surname><given-names>MP</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Immunoimaging: studying immune system dynamics using two-photon microscopy</article-title><source>Cold Spring Harbor Protocols</source><volume>2011</volume><elocation-id>pdb.top99</elocation-id><pub-id pub-id-type="doi">10.1101/pdb.top99</pub-id><pub-id pub-id-type="pmid">21285279</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Wei</surname><given-names>SH</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Two-photon imaging of lymphocyte motility and antigen response in intact lymph node</article-title><source>Science</source><volume>296</volume><fpage>1869</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1126/science.1070051</pub-id><pub-id pub-id-type="pmid">12016203</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrass</surname><given-names>P</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Daxini</surname><given-names>S</given-names></name><name><surname>Lasaro</surname><given-names>MO</given-names></name><name><surname>Iparraguirre</surname><given-names>A</given-names></name><name><surname>Cavanagh</surname><given-names>LL</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name><name><surname>Ertl</surname><given-names>HC</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name><name><surname>Weninger</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Random migration precedes stable target cell interactions of tumor-infiltrating T cells</article-title><source>Journal of Experimental Medicine</source><volume>203</volume><fpage>2749</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1084/jem.20060710</pub-id><pub-id pub-id-type="pmid">17116735</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukai</surname><given-names>S</given-names></name><name><surname>Kjaergaard</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>S</given-names></name><name><surname>Plautz</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy</article-title><source>Cancer Research</source><volume>59</volume><fpage>5245</fpage><lpage>5249</lpage><pub-id pub-id-type="pmid">10537304</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahara</surname><given-names>T</given-names></name><name><surname>Uchi</surname><given-names>H</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><name><surname>Avogadri</surname><given-names>F</given-names></name><name><surname>Rizzuto</surname><given-names>GA</given-names></name><name><surname>Hirschhorn-Cymerman</surname><given-names>D</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Houghton</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs</article-title><source>Blood</source><volume>115</volume><fpage>4384</fpage><lpage>4392</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-11-251231</pub-id><pub-id pub-id-type="pmid">20154220</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulatory T cells in cancer immunotherapy</article-title><source>Current Opinion in Immunology</source><volume>27</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2013.12.005</pub-id><pub-id pub-id-type="pmid">24413387</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleinika</surname><given-names>K</given-names></name><name><surname>Nibbs</surname><given-names>RJ</given-names></name><name><surname>Graham</surname><given-names>GJ</given-names></name><name><surname>Fraser</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Suppression, subversion and escape: the role of regulatory T cells in cancer progression</article-title><source>Clinical &amp; Experimental Immunology</source><volume>171</volume><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2012.04657.x</pub-id><pub-id pub-id-type="pmid">23199321</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagès</surname><given-names>F</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>M-C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Sautès-Fridman</surname><given-names>C</given-names></name><name><surname>Fridman</surname><given-names>W-H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Immune infiltration in human tumors: a prognostic factor that should not be ignored</article-title><source>Oncogene</source><volume>29</volume><fpage>1093</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.416</pub-id><pub-id pub-id-type="pmid">19946335</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>GM</given-names></name><name><surname>Fontanella</surname><given-names>AN</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Hanna</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Fraser</surname><given-names>CL</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters</article-title><source>Nature Protocols</source><volume>6</volume><fpage>1355</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1038/nprot.2011.349</pub-id><pub-id pub-id-type="pmid">21886101</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perentes</surname><given-names>JY</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Visualizing anti-tumor immune responses in vivo</article-title><source>Disease Models and Mechanisms</source><volume>2</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1242/dmm.001842</pub-id><pub-id pub-id-type="pmid">19259379</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccard</surname><given-names>H</given-names></name><name><surname>Muschel</surname><given-names>RJ</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>On the dual roles and polarized phenotypes of neutrophils in tumor development and progression</article-title><source>Critical Reviews in Oncology/Hematology</source><volume>82</volume><fpage>296</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2011.06.004</pub-id><pub-id pub-id-type="pmid">21798756</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>CR</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Wojtkiewicz</surname><given-names>G</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>In vivo imaging of T cell delivery to tumors after adoptive transfer therapy</article-title><source>PNAS</source><volume>104</volume><fpage>12457</fpage><lpage>12461</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704460104</pub-id><pub-id pub-id-type="pmid">17640914</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>BZ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Recent Progress in multifocal Multiphoton Microscopy</article-title><source>Journal of Innovative Optical Health Science</source><volume>5</volume><elocation-id>1250018</elocation-id><pub-id pub-id-type="doi">10.1142/s1793545812500186</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radojcic</surname><given-names>V</given-names></name><name><surname>Bezak</surname><given-names>KB</given-names></name><name><surname>Skarica</surname><given-names>M</given-names></name><name><surname>Pletneva</surname><given-names>MA</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><name><surname>Luznik</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination</article-title><source>Cancer Immunology, Immunotherapy</source><volume>59</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0734-3</pub-id><pub-id pub-id-type="pmid">19590872</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adoptive immunotherapy for cancer: harnessing the T cell response</article-title><source>Nature Reviews Immunology</source><volume>12</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/nri3191</pub-id><pub-id pub-id-type="pmid">22437939</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Restifo</surname> <given-names>WWO</given-names></name><name><surname>Nicholas</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><person-group person-group-type="editor"><name><surname>Rechard</surname> <given-names>C</given-names></name></person-group><source>Current Protocols in Immunology</source><publisher-loc>Hoboken, NJ</publisher-loc><publisher-name>Wiley interscience: John Wiley &amp; Sons</publisher-name><pub-id pub-id-type="doi">10.1002/0471142735</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Adoptive cell transfer: a clinical path to effective cancer immunotherapy</article-title><source>Nature Reviews Cancer</source><volume>8</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/nrc2355</pub-id><pub-id pub-id-type="pmid">18354418</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruocco</surname><given-names>MG</given-names></name><name><surname>Pilones</surname><given-names>KA</given-names></name><name><surname>Kawashima</surname><given-names>N</given-names></name><name><surname>Cammer</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Babb</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Dustin</surname><given-names>ML</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>3718</fpage><lpage>3730</lpage><pub-id pub-id-type="doi">10.1172/JCI61931</pub-id><pub-id pub-id-type="pmid">22945631</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Sistigu</surname><given-names>A</given-names></name><name><surname>Valentini</surname><given-names>M</given-names></name><name><surname>Mattei</surname><given-names>F</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>Spadaro</surname><given-names>F</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Lorenzi</surname><given-names>S</given-names></name><name><surname>D'Urso</surname><given-names>MT</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><name><surname>Gabriele</surname><given-names>L</given-names></name><name><surname>Proietti</surname><given-names>E</given-names></name><name><surname>Bracci</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis</article-title><source>Cancer Research</source><volume>71</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2788</pub-id><pub-id pub-id-type="pmid">21156650</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schietinger</surname><given-names>A</given-names></name><name><surname>Arina</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>RB</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Engels</surname><given-names>B</given-names></name><name><surname>Bindokas</surname><given-names>V</given-names></name><name><surname>Bartkowiak</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name><name><surname>Piston</surname><given-names>DW</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Zal</surname><given-names>T</given-names></name><name><surname>Schreiber</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer</article-title><source>OncoImmunology</source><volume>2</volume><elocation-id>e26677</elocation-id><pub-id pub-id-type="doi">10.4161/onci.26677</pub-id><pub-id pub-id-type="pmid">24482750</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion</article-title><source>Science</source><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sistigu</surname><given-names>A</given-names></name><name><surname>Viaud</surname><given-names>S</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Bracci</surname><given-names>L</given-names></name><name><surname>Proietti</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Immunomodulatory effects of cyclophosphamide and implementations for vaccine design</article-title><source>Seminars in Immunopathology</source><volume>33</volume><fpage>369</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1007/s00281-011-0245-0</pub-id><pub-id pub-id-type="pmid">21611872</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skelton</surname><given-names>D</given-names></name><name><surname>Satake</surname><given-names>N</given-names></name><name><surname>Kohn</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice</article-title><source>Gene Therapy</source><volume>8</volume><fpage>1813</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301586</pub-id><pub-id pub-id-type="pmid">11803402</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumen</surname><given-names>C</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Mazo</surname><given-names>IB</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Intravital microscopy: visualizing immunity in context</article-title><source>Immunity</source><volume>21</volume><fpage>315</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.08.006</pub-id><pub-id pub-id-type="pmid">15357943</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Sunshine</surname><given-names>MJ</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Butcher</surname><given-names>E</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse</article-title><source>Journal of Immunology</source><volume>165</volume><fpage>3284</fpage><lpage>3292</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.6.3284</pub-id><pub-id pub-id-type="pmid">10975845</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veltman</surname><given-names>JD</given-names></name><name><surname>Lambers</surname><given-names>MEH</given-names></name><name><surname>van Nimwegen</surname><given-names>M</given-names></name><name><surname>de Jong</surname><given-names>S</given-names></name><name><surname>Hendriks</surname><given-names>RW</given-names></name><name><surname>Hoogsteden</surname><given-names>HC</given-names></name><name><surname>Aerts</surname><given-names>JGJV</given-names></name><name><surname>Hegmans</surname><given-names>JPJJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity</article-title><source>Journal of Biomedicine and Biotechnology</source><volume>2010</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2010/798467</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignali</surname><given-names>DA</given-names></name><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>How regulatory T cells work</article-title><source>Nature Reviews Immunology</source><volume>8</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nri2343</pub-id><pub-id pub-id-type="pmid">18566595</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kiniwa</surname><given-names>Y</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Wang</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy</article-title><source>Immunity</source><volume>20</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(03)00359-5</pub-id><pub-id pub-id-type="pmid">14738769</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>S</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In Vivo Visualization of Tumor Antigen-containing Microparticles Generated in Fluorescent-protein-elicited Immunity</article-title><source>Theranostics</source><volume>6</volume><fpage>1453</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.7150/thno.14145</pub-id><pub-id pub-id-type="pmid">27375792</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Matsushima</surname><given-names>H</given-names></name><name><surname>Ohtola</surname><given-names>JA</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Takashima</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutrophil priming occurs in a sequential manner and can be visualized in living animals by monitoring IL-1β promoter activation</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>1211</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402018</pub-id><pub-id pub-id-type="pmid">25527787</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Byrd</surname><given-names>D</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name><name><surname>Roche</surname><given-names>P</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells</article-title><source>PNAS</source><volume>99</volume><fpage>16168</fpage><lpage>16173</lpage><pub-id pub-id-type="doi">10.1073/pnas.242600099</pub-id><pub-id pub-id-type="pmid">12427970</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels</article-title><source>Cancer Research</source><volume>70</volume><fpage>4850</fpage><lpage>4858</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0283</pub-id><pub-id pub-id-type="pmid">20501849</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zippelius</surname><given-names>A</given-names></name><name><surname>Batard</surname><given-names>P</given-names></name><name><surname>Rubio-Godoy</surname><given-names>V</given-names></name><name><surname>Bioley</surname><given-names>G</given-names></name><name><surname>Liénard</surname><given-names>D</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Guillaume</surname><given-names>P</given-names></name><name><surname>Meidenbauer</surname><given-names>N</given-names></name><name><surname>Mackensen</surname><given-names>A</given-names></name><name><surname>Rufer</surname><given-names>N</given-names></name><name><surname>Lubenow</surname><given-names>N</given-names></name><name><surname>Speiser</surname><given-names>D</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance</article-title><source>Cancer Research</source><volume>64</volume><fpage>2865</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3066</pub-id><pub-id pub-id-type="pmid">15087405</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulatory T cells, tumour immunity and immunotherapy</article-title><source>Nature Reviews Immunology</source><volume>6</volume><fpage>295</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/nri1806</pub-id><pub-id pub-id-type="pmid">16557261</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.14756.073</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cao</surname><given-names>Xuetao</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Zhejiang University School of Medicine</institution>, <country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Xuetao Cao as the Reviewing Editor and Sean Morrison as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Michael Hamblin (peer reviewer).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>By using intravital microscopy and a skin-fold window chamber models, the authors investigated spatio-temporal dynamics of immune cell subset infiltration and interaction in B16 melanoma-bearing mice receiving a combined chemoimmunotherapy of ACT plus CTX, and showed that Tregs could form an immunosuppressive ring around the CFP-B16 tumor that could be prevented by ACT and CTX. They also showed the dynamic process of the migration of adoptive CTLs into the tumor after selective depletion of Tregs by CTX treatment, and combined chemoimmunotherapy could also activate endogenous neutrophils and mature dendritic cells to infiltrate the tumor. Overall, the findings are interesting, contributing to better understanding of the improved efficacy of combined chemoimmunotherapy and providing translational potential in cancer therapy. However, some concerns should be addressed to improve the quality of this work.</p><p>Essential revisions:</p><p>The authors should select low-dose cyclophosphamide (50 mg/kg, but not 150 mg/kg) to repeat the in vivo therapeutic regimen and then observe the spatio-temporal dynamics of immune cell subset infiltration in B16 tumor. This would address multiple issues raised by multiple reviewers. What about the activation of endogenous CTLs by the combined immunotherapy, and how can you distinguish the infiltration of adoptively transferred CTLs and the endogenous CTLs? This also must be addressed.</p><p><italic>Reviewer #1:</italic></p><p>This paper uses in vivo fluorescence imaging of a multi-color coded fluorescent mouse tumor model to study immunotherapy with adoptive T cell transfer (ACT) and low dose cyclophosphamide (CTX). The main finding was that Tregs could form an immunosuppressive ring around the tumor that could be prevented by ACT and CTX. They also found that the treatment could activate endogenous neutrophils and mature dendritic cells to infiltrate the tumor.</p><p>1) They obtained the CTLs for adoptive transfer from mice that had been immunized using mitomycin C treated CFP-B16 cells. However, they have ignored a large body of work that treatments that produce damage-associated molecular patterns (DAMPs) in the tumor cells are more effective when used in vaccination protocols. DAMPs on the killed tumor cells are better able to activate dendritic cells.</p><p>2) As the authors will be aware there is considerable disagreement on the best dose for low-dose cyclophosphamide. Here they used 150 mg/kg which in my experience is quite high. In mice 50 mg/kg is more usual.</p><p>3) They have ignored several papers that have shown that fluorescent proteins (GFP) expressed in the tumor can act as tumor-associated antigens. How do they know that the CFP in the B16 tumor did not play a major role in the response?</p><p>4) They did not mention the activation of endogenous CTLs by the treatment. However, they did stain the tumors with anti-CD3 but it is not clear if they could distinguish between adoptive and endogenous T-cells.</p><p>5) If all the endogenous nucleated cells were stained with EGFP how could they distinguish between fibroblasts and endothelial cells and TIIs?</p><p>6) They have not mentioned the use of checkpoint inhibitors which is somewhat strange considering the enormous impact they have made in immune-oncology.</p><p>7) I think the Abstract needs more hard information; for instance about which cells were fluorescently labeled and something about the widow chamber and cell tracking. &quot;immunosuppressive ring&quot; is repeated twice.</p><p><italic>Reviewer #2:</italic></p><p>This manuscript by Dr. Zhang and colleagues focuses on spatio-temporal dynamics of immunocytes in B16 tumor bearing mice. Using intravital microscopy and a skin-fold window chamber model, the authors observed an &quot;immunosuppressive ring&quot; formed by Tregs surrounded the CFP-B16 tumor. This is an interesting paper addressing the dynamic process of the migration of adoptive CTLs into the tumor after selective depletion of Tregs by CTX treatment. Its principal finding is to demonstrate that the four stages migratory behavior of adoptive CTLs, including the mean velocity, confinement ratio and arrest coefficient, in the tumor microenvironment after CTX-ACT treatment. According to this finding, the authors designed a metronomic schedule of CTX-ACT treatment improving the anti-tumor efficacy of the combined immunotherapy, which has translational potential in cancer therapy. The comments are listed below for the authors' consideration.</p><p>1) In <xref ref-type="fig" rid="fig1">Figure 1</xref>, the authors isolated splenic and lymph node cells from B16 cell-vaccinated mice and cultured them in vitro with B16 lysates to amplify the cells for melanoma-specific CTL preparation. This method is rough. The authors should use CTLs from OT-I transgenic C57BL/6 mouse and OVA-B16 melanoma cells to further confirm the result.</p><p>2) In <xref ref-type="fig" rid="fig2">Figure 2</xref>, CTX is an immunosuppressive reagent and only low-dose CTX may function to selectively deplete Treg cells. The authors did not use low dose metronomic CTX but selected high dose CTX (150mg/kg) for the treatment. The authors should at least show the change of Treg cells and conventional T cells after 150 mg/kg CTX treatment.</p><p>3) In <xref ref-type="fig" rid="fig3">Figure 3</xref>, the authors used TII to instead TIL, which was weird.</p><p>4) In <xref ref-type="fig" rid="fig6">Figure 6</xref>, the authors emphasized the infiltration of DCs with mature phenotype. The data were not very strong.</p><p>5) In <xref ref-type="fig" rid="fig7">Figure 7</xref>, the authors designed the metronomic schedule of CTX-ACT treatment by 150 mg/kg CTX for treatment on day 4, day 9 and day 14. The author should provide more data to separate two possible consequences in order to explain the combined treatment. One was such dose CTX treatment only targeted Treg cells, thus relieving immune suppression. Another was such dose CTX resulted in much decrease of total T cell number, thus providing space for amplification of those adoptively transferred T cells.</p><p>6) Recognition of cognate antigen is essential for T cell to contact and attack tumor cell, however, chemokine is the most important factor regulating the T cells infiltration into tumor site. Please provide the rationale for why Treg cell depletion resulted in CTL accumulation.</p><p>7) Please provide more evidence to distinguish neutrophils and PMN-MDSCs.</p><p>8) In Figure 5—figure supplement 1B, the morphology of tumor cells between the PBS/ACT group and the CTX/CTX+ACT group is different. Was the scale bar different?</p><p>9) The English needs much improvement.</p><p><italic>Reviewer #3:</italic> </p><p>This study by Qi et al. is very interesting! It revealed sequential anti-tumor immune responses, including adoptive cell therapy and host immune responses, in vivo in real time. The paper is clearly written.</p><p><xref ref-type="fig" rid="fig2">Figure 2A</xref> shows no difference in tumor growth between CTX and CTX + ACT treated group. Dose this suggest CTL infiltrating tumors is not so important?</p><p><xref ref-type="fig" rid="fig2">Figure 2B and C</xref>: it would be helpful to quantify the Tregs and CTLs, as well as tumor &quot;shrinking&quot; and &quot;melting&quot;, not only in CTX +ACT group but also other treatment groups. How many mice have been examined?</p><p>Does the number of infiltrating adoptive CTL inversely correlate with tumor growth?</p><p><xref ref-type="fig" rid="fig4">Figure 4</xref>: It is would be very interesting to know the phenotype of the endogenous EGFP+ cells TIIs. Are there any CD8<sup>+</sup> TILs or CD4<sup>+</sup> Tregs? Co-staining will help.</p><p>Figure 5—figure supplement 1, Is there a significant difference in% neutrophil between the CTX and CTX-ACT treatment groups? It seems there is no difference, which suggests that neutrophil infiltration is the result of CTX. It seems there are not so many endogenous CD3+ T cells in the tumor. Does this mean that tumor elimination is mainly due to ACT?</p><p>In the subsection “Both CTX and ACT treatments are the essential factors for the chemotaxis and recruitment of TIIs into the tumor parenchyma”: &quot;Among all of these groups, only the CTX-ACT treatment group resulted in the TIIs moving toward the tumor parenchyma…&quot;. It is hard to understand why only CTX-ACT, but neither CTX nor ACT treatment alone, induces this. Is it because those endogenous cells recognized something on the adoptively transferred CTLs or the transferred cells produced some factors to activate endogenous cells or promote their migration?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.14756.074</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>[…]</italic></p><p><italic>Essential revisions:</italic></p><p><italic>The authors should select low-dose cyclophosphamide (50 mg/kg, but not 150 mg/kg) to repeat the</italic> in vivo <italic>therapeutic regimen and then observe the spatio-temporal dynamics of immune cell subset infiltration in B16 tumor. This would address multiple issues raised by multiple reviewers.</italic></p><p>Thank you for this valuable suggestion. The dose of cyclophosphamide (CTX) was the first thing we considered for designing the CTX-ACT combined treatment for CFP-B16 tumors. Previous reports used CTX doses between 30 and 200 mg kg<sup>-1</sup> for the CTX-mediated Tregs suppression in mice (Ghiringhelli et al. 2004, Ercolini et al. 2005, Lutsiak et al. 2005, Motoyoshi et al. 2006). In different mouse tumor models, effective CTX doses between 50 and 150 mg kg<sup>-1</sup> were applied for enhancing anti-tumor immune effects (Machiels et al. 2001, Le and Jaffee 2012), while a CTX dose range between 100 and 250 mg kg<sup>-1</sup> was used in B16 melanoma chemoimmunotherapy (Sistigu et al. 2011).</p><p>In order to select a suitable CTX dose for CFP-B16 treatment, we determined the optimal dose experimentally. Therefore, we performed CFP-B16 tumor growth inhibition experiments with different CTX doses (50, 100, and 150 mg kg<sup>-1</sup>) on 4 days after 5 × 10<sup>5</sup> CFP-B16 cells implanted into immuno-competent C57BL/6 mice and immuno-deficient BALB/c nude mice. These experiments confirmed that the anti-tumor effect of the CTX treatment with CTX doses between 50 and 150 mg kg<sup>–1</sup> is not caused by the direct cytotoxicity of CTX, as no difference in the inhibition of tumor growth in immune-deficient mice (nude) was observed between the PBS control group and mice treated with different doses of CTX (50, 100, and 150 mg kg<sup>-1</sup>). In immune-competent mice (C57BL/6), the CFP-B16 tumor growth was significantly inhibited by treatment with 150 mg kg<sup>–1</sup> CTX with or without adoptive T cells (ACT) in comparison to treatment with lower CTX doses of 50 and 100 mg kg<sup>-1</sup> with or without ACT as well as PBS control groups. More importantly, CTX in lower doses (50 and 100 mg kg<sup>-1</sup>) with or without ACT failed to control the tumor growth and showed no significant difference to the PBS control group (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). These results suggest that the efficacy of the CTX treatment for CFP-B16 tumors depends on the enhanced anti-tumor immune response, but not on the direct cytotoxicity of CTX. According to the results of the CFP–B16 tumor growth inhibition experiments, we finally selected a CTX dose of 150 mg kg<sup>-1</sup> for the CTX and CTX-ACT combined treatment.</p><p>To address this question, we added a new figure (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and sentences in the Results to illustrate this question:</p><p>“This CTX dose was selected based on CFP-B16 tumor inhibition experiments with different CTX doses. […] Furthermore, by the tumor growth inhibition experiment performed on the BALB/c nude mice, we confirmed that the effective anti-tumor effect of CTX at the dose of 150 mg kg<sup>-1</sup> is not due to its direct cytotoxicity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).”</p><p><italic>What about the activation of endogenous CTLs by the combined immunotherapy, and how can you distinguish the infiltration of adoptively transferred CTLs and the endogenous CTLs? This also must be addressed.</italic></p><p>We designed two experiments to answer this question: the ex vivo characterization of endogenous T cells in the CFP-B16 tumors, and the intravital imaging of endogenous CTLs and adoptive CTLs in tumor areas on day 5 after the combined CTX-ACT treatment.</p><p>Here, we used transgenic mice (<italic>Cxcr6<sup>+/gfp</sup></italic>) with the Cxcr6 sequence on one allele and the GFP replace CXCR6 coding region on the other allele, in which GFP cells with CD8<sup>+</sup> marker represent endogenous CTLs (Unutmaz et al. 2000, Ruocco et al. 2012). We analyzed endogenous GFP cells in tumors of mice treated with PBS, ACT, CTX, and CTX-ACT on Day 5 (five days after ACT treatment and 11 days after implantation of CFP-B16 cells) by flow cytometry. This analysis showed that: (1) the number of endogenous GFP cells in the tumors of the CTX treatment group was significantly decreased with respect to the non-CTX treatment groups (1.31% versus 3.57%) and (2) most GFP cells (more than 60%) were CD8<sup>+</sup> CTLs expressed with the activation marker CD69 in the tumors of CTX-ACT treated mice.</p><p>In order to distinguish adoptive and endogenous CTLs by intravital imaging, the adoptive CTLs were labeled with the red fluorescent dye CMTPX and transferred into <italic>Cxcr6<sup>+/gfp</sup></italic> transgenic mice with CFP-B16 tumor cells implanted into the window chamber. The imaging data showed that the number of endogenous GFP T cells in the tumor areas of CTX treatment mice was much less than that in non-CTX treatment mice. The analysis of the dynamic behavior of the endogenous T cells showed that the mean velocity of the endogenous GFP T cells in CTX-ACT-treated mice was significantly decreased compared with ACT-treated mice (3.80 ± 2.56 μm min<sup>-1</sup> in the CTX-ACT group versus 4.6 ± 2.0 μm min<sup>-1</sup> in the ACT group).</p><p>Thus, both ex vivo characterization and intravital imaging suggest that the combined CTX–ACT treatment deleted most of the endogenous CD4<sup>+</sup> T cells and retained the activated endogenous CTLs in the tumor area. The activated endogenous CTLs arrested in the tumor area and formed stable, long-lasting interactions with tumor cells to kill them efficiently.</p><p>To address this question, we added to the main manuscript a new section “CTX-ACT treatment decreased total endogenous T cells but retained activated endogenous CTLs in the tumor microenvironment” and two new figures (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p><bold>“</bold>CTX-ACT treatment decreased total endogenous T cells but retained activated endogenous CTLs in the tumor microenvironment</p><p>Next, we studied the dynamic behavior of endogenous CTLs in the tumor area. Here, we used <italic>Cxcr6<sup>+/gfp</sup></italic> transgenic mice that carried the CXCR6 sequence on one allele and the GFP replace CXCR6 coding region on the other allele, in which GFP cells with the CD8<sup>+</sup> marker represent endogenous CTLs (Unutmaz et al. 2000, Ruocco et al. 2012). […] Both ex vivo characterization experiments and intravital imaging suggested that the CTX-ACT combined treatment deleted most of the endogenous CD4<sup>+</sup> T cells and retained the activated endogenous CTLs in the tumor area. The activated endogenous CTLs arrested in the tumor area for a long time and built stable, long-lasting interactions with the tumor cells to kill them efficiently.”</p><p><italic>Reviewer #1:</italic></p><p><italic>[…]</italic></p><p><italic>1) They obtained the CTLs for adoptive transfer from mice that had been immunized using mitomycin C treated CFP-B16 cells. However, they have ignored a large body of work that treatments that produce damage-associated molecular patterns (DAMPs) in the tumor cells are more effective when used in vaccination protocols. DAMPs on the killed tumor cells are better able to activate dendritic cells.</italic></p><p>We examined the released DAMPs in mitomycin C-treated CFP-B16 cells. The results demonstrated that although the mitomycin C treatment did not increase the release of DAMPs from CFP-B16 tumor cells, a small amount of DAMPs is released in the suspension of mitomycin C- treated CFP-B16 cells, which is beneficial for the activation of DC.</p><p><italic>2) As the authors will be aware there is considerable disagreement on the best dose for low-dose cyclophosphamide. Here they used 150 mg/kg which in my experience is quite high. In mice 50 mg/kg is more usual.</italic></p><p>Thank you for this suggestion. The selection of a CTX dose of 150 mg kg<sup>-1</sup> instead of 50 mg kg<sup>-1</sup> was based on literature values and the results of our tumor therapy experiments (details are shown in the “Essential Revisions 1”). The tumor therapy experiments confirmed that in comparison with other doses, the CTX dose of 150 mg kg<sup>-1</sup> exhibited good efficacy to control the growth of CFP-B16 tumors, and the anti-tumor effect is due to the induced immune response but not related to direct cytotoxicity. Please see our response to Essential Revisions 1 for more details.</p><p><italic>3) They have ignored several papers that have shown that fluorescent proteins (GFP) expressed in the tumor can act as tumor-associated antigens. How do they know that the CFP in the B16 tumor did not play a major role in the response?</italic></p><p>In our study, the mitomycin C was used as the inhibitor of DNA proliferation of CFP-B16 tumor cells to get the whole-cell antigens to immunize the mice. To the best of our knowledge, mitomycin C does not induce the release of DAMPs from tumor cells when being used as cancer chemotherapy drugs (Tomasz 1995, Krysko et al. 2012). To answer this question, we performed the Western blot to detect the released DAMPs (including HMGB1 and Hsp70) in the supernatant and whole-cell lysates (as positive control) of CFP-B16 cells and B16 cells treated with or without mitomycin C (MMC). The results showed that both MMC-treated CFP-B16 and B16 tumor cells as well as non MMC-treated cells released a certain amount of DAMPs (Author response image). When C57BL/6 mice had been immunized with whole-cell suspension of MMC-treated CFP-B16 cells (2.5 × 10<sup>6</sup> cells in 300 μL PBS), a certain amount of released DAMPs also promoted the activation of DCs (Krysko et al. 2012), which were beneficial for generating CFP-B16 specific CTLs.<fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.069</object-id><label>Author response image 1.</label><caption><title>Western blot of DAMPs expression in supernatants or whole-cell lysates of mitomycin C treated B16 cells, non-mitomycin C-treated B16 cells, mitomycin C-treated CFP-B16 cells, and non-mitomycin C-treated CFP-B16 cells.</title><p>Supernatants are normalized to the cell numbers.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.069">http://dx.doi.org/10.7554/eLife.14756.069</ext-link></p></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-14756-resp-fig1-v2"/></fig></p><p><italic>4) They did not mention the activation of endogenous CTLs by the treatment. However, they did stain the tumors with anti-CD3 but it is not clear if they could distinguish between adoptive and endogenous T-cells.</italic></p><p>Thank you for the suggestion. We have replied this question at “Essential revision 2”.</p><p><italic>5) If all the endogenous nucleated cells were stained with EGFP how could they distinguish between fibroblasts and endothelial cells and TIIs?</italic></p><p>For intravital imaging of the tumor microenvironment in EGFP-transgenic C57BL/6 mice, TIIs were identified from fibroblasts and endothelial cells according to their size, shape, and dynamic movement, as described in previous studies (Miller et al. 2002, Condeelis and Segall 2003, Mrass et al. 2006, McDonald et al. 2010, Yang et al. 2016). Furthermore, Furthermore, we identified the EGFP cells in situ by immunofluorescence histological analysis (Figure 6—figure supplement 2 A: CD3, Ly6G and F4/80), as described in the main manuscript.</p><p><italic>6) They have not mentioned the use of checkpoint inhibitors which is somewhat strange considering the enormous impact they have made in immune-oncology.</italic></p><p>Thank you for this good suggestion. The aim of this paper was to develop an excellent method for the in vivo detection of the spatio-temporal characteristics of various immune cells in the tumor microenvironment. This method is also suitable for monitoring the immune reaction of tumor-bearing mice treated with checkpoint inhibitors and comparing the efficacy between classical immunotherapy (such as the CTX-ACT combined treatment) and checkpoint inhibitors. In response to this concern, we added a sentence to the Discussion section:</p><p>“Furthermore, the method of long-term intravital imaging of various immune cells in the tumor microenvironmentin vivo is also suitable for monitoring multiple immune reactions, studying the spatio-temporal cellular events of other immunotherapies, such as checkpoint inhibitors (CTLA-4 antibody and PD-1/PD-L1 antibodies), and comparing the efficacy between classical immunotherapies (such as the CTX-ACT combined treatment) and checkpoint inhibitors on the treatments of different tumor models.”</p><p><italic>7) I think the Abstract needs more hard information; for instance about which cells were fluorescently labeled and something about the widow chamber and cell tracking. &quot;immunosuppressive ring&quot; is repeated twice.</italic></p><p>Thank you for the suggestion, we rewrote the Abstract:</p><p>“The combined-immunotherapy of adoptive cell therapy (ACT) and cyclophosphamide (CTX) is one of the most efficient treatments for melanoma patients. […] These insights into the spatio-temporal dynamics of immunocytes are beneficial for optimizing immunotherapy and provide new approaches for elucidating the mechanisms underlying the involvement of immunocytes in cancer immunotherapy.”</p><p><italic>Reviewer #2:</italic></p><p><italic>This manuscript by Dr. Zhang and colleagues focuses on spatio-temporal dynamics of immunocytes in B16 tumor bearing mice. Using intravital microscopy and a skin-fold window chamber model, the authors observed an &quot;immunosuppressive ring&quot; formed by Tregs surrounded the CFP-B16 tumor. This is an interesting paper addressing the dynamic process of the migration of adoptive CTLs into the tumor after selective depletion of Tregs by CTX treatment. Its principal finding is to demonstrate that the four stages migratory behavior of adoptive CTLs, including the mean velocity, confinement ratio and arrest coefficient, in the tumor microenvironment after CTX-ACT treatment. According to this finding, the authors designed a metronomic schedule of CTX-ACT treatment improving the anti-tumor efficacy of the combined immunotherapy, which has translational potential in cancer therapy. The comments are listed below for the authors' consideration.</italic></p><p><italic>1) In <xref ref-type="fig" rid="fig1">Figure 1</xref>, the authors isolated splenic and lymph node cells from B16 cell-vaccinated mice and cultured them</italic> in vitro <italic>with B16 lysates to amplify the cells for melanoma-specific CTL preparation. This method is rough. The authors should use CTLs from OT-I transgenic C57BL/6 mouse and OVA-B16 melanoma cells to further confirm the result.</italic></p><p>As mentioned in our manuscript, various reported studies have used the OT-I system with K<sup>b</sup>-OVA as a model antigen in T lymphoma cells and also in B16 melanoma cells. According to these reports, CTLs separated from OT-I transgenic C57BL/6 mice that displayed efficient tumor-killing abilities when they were transferred to mice bearing OVA-tumors (Kircher et al. 2003, Boissonnas et al. 2007, Shurin et al. 2009). Our unpublished results also confirmed that the adoptively transferred CTLs from OT-I mice completely eliminated the OVA-B16 tumors without any CTX treatment. However, unlike OVA are expressed in OVA-tumor cells, tumor antigens are usually expressed at a low level in most patients (Restifo, Dudley, and Rosenberg 2012). Thus, to mimic ACT immunotherapy in clinic, we chose an experimental system by using whole tumor cell antigens to prime and activate the CTLs. The method of generation B16-specific CTL refers to the book “Current protocols in Immunology” (Restifo 2011) and previous reports (Liu et al. 2006, Bauer et al. 2014). In response to this concern, we re-phrased the sentence in the Results as follows:</p><p>“To assess the curative efficacy of ACT on the murine melanoma <italic>in vivo</italic>, CTLs were obtained from the splenocytes of C57BL/6 mice immunized with mitomycin C pre-treated B16 melanoma cells according to previous protocols (Restifo 2011) and reports (Liu et al. 2006, Bauer et al. 2014).”</p><p><italic>2) In <xref ref-type="fig" rid="fig2">Figure 2</xref>, CTX is an immunosuppressive reagent and only low-dose CTX may function to selectively deplete Treg cells. The authors did not use low dose metronomic CTX but selected high dose CTX (150mg/kg) for the treatment. The authors should at least show the change of Treg cells and conventional T cells after 150 mg/kg CTX treatment.</italic></p><p>As the reviewer suggested, we detected CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the blood of mice on days 5, 7, 11, 13, and 15 after implantation of 5 × 10<sup>5</sup> CFP–B16 tumor cells. The mice were metronomically treated with 150 mg kg<sup>-1</sup> CTX (intraperitoneally injected on days 4, 9, and 14) or PBS. The results showed that, compared with the PBS controls, the metronomic CTX treatments successively decreased the percentage of CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the blood of mice on days 11, 13, and 15 (1.44, 1.1, and 0.7% in the CTX group versus 2.28, 1.34, and 1.22% in the PBS group) and successively increased the percentage of CD4<sup>+</sup> T and CD8<sup>+</sup> T cells in the blood of mice on days 11 and 13 (29 and 31% in the CTX group versus 20.5 and 22% in the PBS group).</p><p>On day 15, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> Tregs were also examined in different organs (including spleens, TDLNs, and tumors) of mice treated with CTX or PBS. Compared with the PBS group, the CTX treatment decreased the percentage of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the spleen (all of them decreased about 50% in the CTX group compared with the PBS group), increased the percentage of CD4<sup>+</sup> T cells (about 1.2-fold increase with respect to the PBS group) and CD8<sup>+</sup> T cells (about 1.7-fold increase with respect to the PBS group) in the TDLN, and decreased the percentage of CD4<sup>+</sup> T cells (about 30% decrease in the CTX group compared with the PBS group) and CD4<sup>+</sup>CD25<sup>+</sup> Tregs (about 50% decrease in the CTX group compared with the PBS group) in the tumor. Notably, the CTX treatment had no effect on the percentage of CD8<sup>+</sup> T cells in the tumor with respect to the PBS group (<xref ref-type="fig" rid="fig11">Author response image 2</xref>).<fig id="fig11" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.070</object-id><label>Author response image 2.</label><caption><title>Alterations in T cell subsets caused by CTX treatment.</title><p>Top row: percentage changes of CD4<sup>+</sup> cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> Tregs in the blood of normal mice, PBS-treated tumor-bearing mice, and CTX metronomically treated tumor-bearing mice on days 5, 7, 11, 13, and 15 after implantation of tumor cells. Bottom row: percentage changes of CD4<sup>+</sup> cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup>CD25<sup>+</sup> Tregs in different organs (spleen, TDLN, and tumor) of normal mice, PBS-treated tumor-bearing mice, and CTX t metronomically treated tumor-bearing mice on day 15.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.070">http://dx.doi.org/10.7554/eLife.14756.070</ext-link></p></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-14756-resp-fig2-v2"/></fig></p><p><italic>3) In <xref ref-type="fig" rid="fig3">Figure 3</xref>, the authors used TII to instead TIL, which was weird.</italic></p><p>TII denotes tumor-infiltrating immunocyte, and TIL denotes tumor-infiltrating lymphocyte. In our experiments, more than 50% of the EGFP immune cells that infiltrated into the tumors were neutrophils and no lymphocytes (Figure 6—figure supplement 2). Therefore, we chose TII to indicate the EGFP-labeled tumor-infiltrating immunocyte instead of TIL.</p><p><italic>4) In <xref ref-type="fig" rid="fig6">Figure 6</xref>, the authors emphasized the infiltration of DCs with mature phenotype. The data were not very strong.</italic></p><p>Thank you for this valuable suggestion. We addressed this question by changing some words in the main manuscript to avoid any misunderstanding. We wanted to emphasize that the number of DCs infiltrating into the tumor area was significantly increased in the CTX-ACT combined treatment group, and some of the infiltrating DCs were mature. Here, we used MHC-II and CD86<sup>+</sup> as the activated phenotype of DCs in the immunofluorescence assay, referring to the previous paper (Schiavoni et al. 2011).</p><p><italic>5) In <xref ref-type="fig" rid="fig7">Figure 7</xref>, the authors designed the metronomic schedule of CTX-ACT treatment by 150 mg/kg CTX for treatment on day 4, day 9 and day 14. The author should provide more data to separate two possible consequences in order to explain the combined treatment. One was such dose CTX treatment only targeted Treg cells, thus relieving immune suppression. Another was such dose CTX resulted in much decrease of total T cell number, thus providing space for amplification of those adoptively transferred T cells.</italic></p><p>Thank you for this good suggestion. Based on our previous data (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig2">Figure 2B,C</xref>) and new data (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B and C</xref> and <xref ref-type="fig" rid="fig11">Author response image 2</xref>), we think both consequences are suitable for explaining the effective anti-tumor immune response of the CTX-ACT combined treatment. The combined treatment not only deleted most Tregs in the tumor areas to block the formation of immunosuppressive ring, but also provided some space for the amplification of adoptive CTLs in the tumor areas. In response to this suggestion, we rewrote the corresponding part in the Discussion section:</p><p>“Additionally, the Tregs depletion induced by CTX treatment contributed to the accumulation of adoptive CTLs in the tumor area by three ways: (1) it cleared the immunosuppressive barrier to facilitates the migration of adoptive CTLs into the tumor area; (2) it induced the high expression of some chemokines and cytokines in the tumor microenvironment to promote the accumulation of adoptive CTLs (Bracci et al. 2007, Schiavoni et al. 2011); and (3) it provided space to allow the infiltration and homeostatic proliferation of adoptive CTLs (Bracci et al. 2007, Sistigu et al. 2011).”</p><p><italic>6) Recognition of cognate antigen is essential for T cell to contact and attack tumor cell, however, chemokine is the most important factor regulating the T cells infiltration into tumor site. Please provide the rationale for why Treg cell depletion resulted in CTL accumulation.</italic></p><p>Thank you for this suggestion. We consider three possible reasons for the CTX treatment-induced Treg depletion, which results in the accumulation of CTLs in the tumor area.</p><p>Reason 1: As mentioned in our manuscript, the Tregs formed an “immunosuppressive ring” around the solid tumor, which blocked the ability of adoptive CTLs to recognize the cognate antigen of the tumor cells and decreased the number of adoptive CTLs migrating into the tumor area. The depletion of Tregs in the tumor area successfully broke this immunosuppressive ring so that adoptive CTLs efficiently penetrated into the tumor area without any barrier formed by immunosuppressive Tregs.</p><p>Reason 2: It has been reported that the Treg depletion due to CTX treatment resulted in the upregulated expression of some chemokines/chemokine receptors and cytokines (e.g., CXCL10/CXCR3 and IL–7) in the tumor area, which promoted CTL infiltration and homeostatic proliferation (Bracci et al. 2007, Schiavoni et al. 2011).</p><p>Reason 3: It has been reported that the proliferation of Tregs proceeds more vigorously than that of CTLs in the tumor area (Taylor, Neujahr, and Turka 2004, Sakaguchi et al. 2008, Sistigu et al. 2011). Thus, the CTX treatment induced the depletion of Tregs and the decrease of other endogenous T cells (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B and C</xref>) in the tumor area, probably providing space for the infiltration and homeostatic proliferation of adoptive CTLs (Bracci et al. 2007, Sistigu et al. 2011).</p><p>In response to this question, we added new sentences in the Discussion to illustrate this question. The additional sentence is presented below.</p><p>“Additionally, the Tregs depletion induced by CTX treatment contributed to the accumulation of adoptive CTLs in the tumor area by three ways: (1) it cleared the immunosuppressive barrier to facilitates the migration of adoptive CTLs into the tumor area; (2) it induced the high expression of some chemokines and cytokines in the tumor microenvironment to promote the accumulation of adoptive CTLs (Bracci et al. 2007, Schiavoni et al. 2011); and (3) it provided space to allow the infiltration and homeostatic proliferation of adoptive CTLs (Bracci et al. 2007, Sistigu et al. 2011).”</p><p><italic>7) Please provide more evidence to distinguish neutrophils and PMN-MDSCs.</italic></p><p>Neutrophils and PMN-MDSCs share the same markers and very hard to distinguish. T Previous reports demonstrated that in the mice the neutrophils and PMN-MDSCs are even functionally similar (Ramachandran et al. 2016). According to the previous papers, we characterized the neutrophils and MDSCs of EGFP cells ex vivo by flow cytometry (<xref ref-type="fig" rid="fig12">Author response image 3</xref>). The markers of neutrophils are CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup>, and markers of MDSCs are CD11b<sup>+</sup>Gr1<sup>+</sup> (Ma and Greten 2016, Ramachandran et al. 2016).<fig id="fig12" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.071</object-id><label>Author response image 3.</label><caption><title>Characterization of the neutrophils and MDSCs of EGFP TIIs ex vivo by flow cytometry.</title><p>The markers of neutrophils are CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup>, and markers of MDSCs are CD11b<sup>+</sup>Gr1<sup>+</sup>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.071">http://dx.doi.org/10.7554/eLife.14756.071</ext-link></p></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-14756-resp-fig3-v2"/></fig></p><p><italic>8) In Figure 5—figure supplement 1B, the morphology of tumor cells between the PBS/ACT group and the CTX/CTX+ACT group is different. Was the scale bar different?</italic></p><p>The scale bars are the same in the PBS, ACT, CTX, and CTX+ACT groups, which can be confirmed by the same morphology of the neutrophils in these four groups. The different morphologies of the tumor cells in the PBS/ACT and CTX/CTX+ACT groups is presumably caused by the anti-tumor immune response induced by the CTX treatment. The HE results showed that the anti-tumor immune response induced by the CTX treatment might affect the morphology of the CFP-B16 tumor cells.</p><p><italic>9) The English needs much improvement.</italic></p><p>Thank you for the suggestion, we have sent the manuscript to American Journal Experts for language editing to improve the quality of English writing.</p><p><italic>Reviewer #3:</italic></p><p><italic>This study by Qi et al. is very interesting! It revealed sequential anti-tumor immune responses, including adoptive cell therapy and host immune responses, in vivo in real time. The paper is clearly written.</italic></p><p><italic><xref ref-type="fig" rid="fig2">Figure 2A</xref> shows no difference in tumor growth between CTX and CTX + ACT treated group. Dose this suggest CTL infiltrating tumors is not so important?</italic></p><p>Thank you for the suggestion, we think that the CTL infiltrating into the tumor area is very important for five reasons.</p><p>Reason 1: In CTX-ACT combined immunotherapy, it takes a long time to trigger the endogenous anti-tumor immune response. Although there was no significant difference in tumor growth control between CTX treatment and CTX-ACT combination treatment group, through intravital imaging, we found that the killing tumor effect were maximized, as well as the increased infiltration and motility of adoptive CTLs, in the CTX-ACT treated mice (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Reason 2: According to our new data (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), the percentage of activated endogenous CD8<sup>+</sup>CD69<sup>+</sup> CTLs in both tumors and TDLNs of the mice treated with CTX-ACT was higher than that of the mice treated with CTX alone (62% versus54% in the tumors, and 25% versus 19.3% in the TDLNs).</p><p>Reason 3: The intravital imaging data revealed that (<xref ref-type="fig" rid="fig6">Figure 6</xref>), compared with CTX treatment, only CTX-ACT treatment induced a rapid and direct movement of the endogenous TIIs toward the tumor parenchyma, which is beneficial for further anti-tumor immune response.</p><p>Reason 4: The intravital imaging data also confirmed that, compared with CTX treatment, only CTX-ACT combined treatment increased the amount of endogenous DCs infiltrating into the tumor area. Some of the infiltrating DCs were mature, which are beneficial for inducing the anti-tumor immune response.</p><p>Reason 5: The three rounds of the metronomic CTX-ACT combined treatment were designed according to intravital imaging information from a single round of the combined treatment. The results showed that the metronomic CTX-ACT treatment successfully controlled the growth of the tumor during its entire course, with a significant difference in the tumor growth control compared with the metronomic CTX treatments (P &lt; 0.05, <xref ref-type="fig" rid="fig8">Figure 8B</xref>).</p><p>For these five reasons, we considered that, besides the CTX treatment, the ACT treatment is also very important for controlling tumor growth. Combining the CTX with the ACT treatment gave synergistic effects on the anti-tumor immune response, which comprised in deleting most of the endogenous immunosuppressive Tregs, increasing the infiltration of adoptive CTLs and endogenous DCs, and accelerating the chemotactic movement of endogenous TIIs toward the tumor parenchyma.</p><p><italic><xref ref-type="fig" rid="fig2">Figure 2B and C</xref>: it would be helpful to quantify the Tregs and CTLs, as well as tumor &quot;shrinking&quot; and &quot;melting&quot;, not only in CTX +ACT group but also other treatment groups. How many mice have been examined?</italic></p><p>Thank you for this suggestion. We imaged 3–4 mice (in two independent imaging experiments) in each group (including the ACT and CTX–ACT groups). To clarify this issue, we updated the figure legend of <xref ref-type="fig" rid="fig2">Figure 2B,C</xref>. We also attempted to quantify Tregs and CTLs in different groups, but evaluated the quantification of Tregs and CTLs as being not sufficiently accurate. The number of Tregs in CTX-ACT treated mice was closed to zero, and the number of adoptive CTLs in mice treated with ACT alone was also close to zero. However, we added the results of this quantification in the <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</p><p><italic>Does the number of infiltrating adoptive CTL inversely correlate with tumor growth?</italic></p><p>Yes, the number of infiltrating adoptive CTLs correlates inversely with the tumor growth. According to the intravital large-field imaging and quantification data (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="fig" rid="fig2">Figure 2B,C</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), the number of infiltrating adoptive CTLs in tumor areas was higher in the CTX-ACT treatment group than in the ACT treatment group, which is consistent with the better tumor growth control in the CTX-ACT treatment group.</p><p><italic><xref ref-type="fig" rid="fig4">Figure 4</xref>: It is would be very interesting to know the phenotype of the endogenous EGFP+ cells TIIs. Are there any CD8<sup>+</sup> TILs or CD4<sup>+</sup> Tregs? Co-staining will help.</italic></p><p>Thank you for this suggestion. According to our previous data, the phenotype of the endogenous EGFP TIIs includes T cells, neutrophils and tumor-associated macrophages (Figure 6—figure supplement 2A). The EGFP TIIs contained few CD8<sup>+</sup> TILs and CD4<sup>+</sup> T cells. We added the confocal imaging and immunofluorescence analysis of CD8<sup>+</sup> TILs and CD4<sup>+</sup> T cells in the <xref ref-type="fig" rid="fig13">Author response image 4</xref>, which the frozen-sections of tumors were incubated with Alexa Fluor 647 anti-mouse CD4 antibody and Alexa Fluor 647 anti-mouse CD8 antibody to identify the endogenous EGFP CD8<sup>+</sup> TILs and CD4<sup>+</sup> T cells.<fig id="fig13" position="float"><object-id pub-id-type="doi">10.7554/eLife.14756.072</object-id><label>Author response image 4.</label><caption><title>Representative tumor sections stained with CD3, CD4, CD8, Ly6G and F4/80.</title><p>Most of the EGFP TIIs at the tumor periphery were Ly6G<sup>+</sup> and F4/80<sup>+</sup>. Scale bar: 50 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14756.072">http://dx.doi.org/10.7554/eLife.14756.072</ext-link></p></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-14756-resp-fig4-v2"/></fig></p><p><italic>Figure 5—figure supplement 1, Is there a significant difference in% neutrophil between the CTX and CTX-ACT treatment groups? It seems there is no difference, which suggests that neutrophil infiltration is the result of CTX. It seems there are not so many endogenous CD3+ T cells in the tumor. Does this mean that tumor elimination is mainly due to ACT?</italic></p><p>Thank you for the suggestion. Here are the answers to the two questions:</p><p>1) The percentage of neutrophils in the CTX–ACT treatment group was slightly higher than in the CTX treatment group, but without significant difference. Although no significant difference was detected between the numbers of neutrophils in the tumor areas of CTX- and CTX-ACT treated mice, the mean velocity of neutrophils was significantly different (<xref ref-type="fig" rid="fig6">Figure 6A,C</xref>). More importantly, only the CTX-ACT combined treatment elicited the chemotactic movement of neutrophils toward the tumor parenchyma (<xref ref-type="fig" rid="fig6">Figure 6</xref>). All these results confirmed that the efficient infiltration of neutrophils is induced by the synergistic effect of CTX and ACT.</p><p>2) Our immunofluorescence analysis of the tumor tissues showed only a small amount of endogenous CD3<sup>+</sup> T cells in the tumor area (Figure 6—figure supplement 2A). According to our new data, the CTX-ACT treatment deleted most of endogenous T cells and only retained activated endogenous CD8<sup>+</sup> CD69<sup>+</sup> CTLs in the tumor areas (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B,C</xref>). These remaining activated endogenous CTLs also exhibited efficient tumor-killing abilities. Besides endogenous T cells, the activated endogenous neutrophils that infiltrated into the tumor area were also directly cytotoxic to the tumor cells (Piccard, Muschel, and Opdenakker 2012). As described in more detail in the answer to the first question of reviewer #3,the elimination of the tumor is due to the synergistic effects of the CTX-ACT combined treatment and failed upon the ACT treatment alone.</p><p><italic>In the subsection “Both CTX and ACT treatments are the essential factors for the chemotaxis and recruitment of TIIs into the tumor parenchyma”: &quot;Among all of these groups, only the CTX-ACT treatment group resulted in the TIIs moving toward the tumor parenchyma…&quot;. It is hard to understand why only CTX-ACT, but neither CTX nor ACT treatment alone, induces this. Is it because those endogenous cells recognized something on the adoptively transferred CTLs or the transferred cells produced some factors to activate endogenous cells or promote their migration?</italic></p><p>Thank you for posing this stimulating question. According to the intravital imaging data (<xref ref-type="fig" rid="fig5">Figures 5</xref>,<xref ref-type="fig" rid="fig6">6</xref>), the synergistic effect of CTX and ACT treatments contributes to trigger the transiently increased chemotactic movement of TIIs toward the tumor parenchyma. The CTX treatment relieved the immunosuppressive microenvironment in the tumor, and promoted the expression of many cytokines (such as GM-CSF and IL-1β)(Bracci et al. 2007) to prime (Yao et al. 2015) the neutrophils and recruit the mature neutrophils into the tumor area. On the other hand, few adoptive CTLs infiltrated into the tumor area as early as 24 h after the ACT treatment; some adoptive CTLs killed tumor cells partially and also released some inflammatory cytokines to further promote the infiltration of endogenous neutrophils. According to the previous reports, the mature neutrophils exhibited high motility and efficient anti-tumor effects (Fridlender et al. 2009, Piccard, Muschel, and Opdenakker 2012, Sagiv et al. 2015). We think that this phenomenon observed by intravital imaging is worth further studies.</p></body></sub-article></article>